Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer
Roche HY 2014 results - Roche - Doing now what patients ...dd773136-361d-45a2-9ddb-a7...Avastin BC...
Transcript of Roche HY 2014 results - Roche - Doing now what patients ...dd773136-361d-45a2-9ddb-a7...Avastin BC...
3
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:1 pricing and product initiatives of competitors;2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing
products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation;10 loss of key executives or other employees; and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.
For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com
All mentioned trademarks are legally protected.
HY 2014: Highlights
5
Regulatory updates
Innovation
1CER=Constant Exchange Rates; 2Breakthrough Therapy Designation; 3Lipopolysaccharide transporter protein D; 4Subcutaneous; 5Platinum resistant
Growth
• EU approval: MabThera SC4
• CHMP positive opinion: Gazyvaro CLL front line, Avastin in ovarian cancer5
• Japan approval: Alectinib in lung cancer
Immunology • EU approval: Actemra SC4
• US approval: Xolair in chronic idiopathic urticaria
Oncology
• Solid sales performance driven by HER2 franchise (+20%1), Avastin (+6%1), Professional Diagnostics (+9%1)
Profit / Cash
Sales
• +7% core EPS growth1, driven largely by strong underlying business • Strong operating free cash flow (+11%1)
• Priority review for Avastin (cervical & ovarian), BTD2 in aPDL1 (bladder), fast track for LptD3 (antibiotic)
• Acquisition of Seragon, IQuum & Genia
2014: 12 new compounds in late stage development
6
Oncology
Neurosciencelampalizumabgeographic atrophy
Immunology /Ophthalmology
ocrelizumabMS
cobimetinib (MEKi)melanoma
lebrikizumabasthma
gantenerumabAlzheimer’s
1Phase 3 decision pending
Bcl-2i (GDC 0199)hem. cancers
alectinib (ALKi)NSCLC
taselisib (PI3Ki)1
solid tumours
pictilisib (PI3Ki)1
solid tumours
polatuzumab (aCD79b)1
hem. cancers
etrolizumabUC and CD
Oncology
Neuroscience
Ophthalmology
Immunology
anti-PDL1solid tumours
HY 2014: Both Divisions growing in all regionsInternational growth increasing in Q2
7
0
2
4
6
8
10
Japan International Europe US
DiagnosticsPharma
+5%
+3%+2%
+7%
+2%
+12%
+4%
+6%
CHFbn
+5%
+3%
+6%
+5%
All growth rates at constant exchange rates (CER)
8
HY 2014: Increase in core operating profit & margin
9.168.25 8.64
9.499.41
37.2% 38.1% 38.5%40.7%
41.0%
HY 2010 HY 2011 HY 2012 HY 2013 HY 2014
+7% at CER
CER=Constant Exchange Rates
CHFbn
9
HY 2014: Continued increase in Core EPS
6.95 6.68 6.887.58
7.57
HY 2010 HY 2011 HY 2012 HY 2013 HY 2014
+7% at CER
CER=Constant Exchange Rates
CHF
Past Service Income (PSI) (–) One-off income previous year
Neupogen (filgrastim) (–) Related gross profit to Amgen
HY 2014: Strong underlying growth
10
Royalties and Other Operating income(+) Sale of filgrastim to Amgen
Underlying business(+) Oncology franchise(+) Immunology & ophthalmology(+) Financial de-leveraging (–) Xeloda
Development Core EPS - HY 2014 +7%
Termination of R&D assets (–) Bitopertin, MetMAb
Planned data presentations in H2 2014
11
Madrid, 26-30 Sep
Avastin BC• HER2-BC (IMELDA)• TML HER2-mBC (TANIA)
Perjeta• (OS data) CLEOPATRA
Zelboraf + Cobimetinib1
• Phase 3 (coBRIM) (planned)
aPDL1• Oral presentations in
monotherapy and combinations
ASH
San Francisco, 6-9 Dec
Gazyva• GREEN study G + various
backbones (planned)
ACE9102
• Hemophilia (planned)
Berlin, 18-21 Oct
mGlu5• MARIGOLD study
(Phase 2 in depression)
Alecensa (alectinib)2
• Japan Phase 1/2 update
Chicago, 30 Oct -1 Nov
Avastin Lung• BEYOND study (planned)
1 In collaboration with Exelixis, 2 In collaboration with Chugai
2014 Outlook
121At constant exchange rates
Group sales growth1 Low- to mid-single digit
Core EPS growth1 Ahead of sales growth
Dividend outlook Further increase dividend
HY 2014: Pipeline update
Regulatory designation
Compound Phase / Meeting
aPDL1: bladder Phase 1 (ASCO1)
BRIM7 (Mek+Braf): melanoma Phase 1 (EADO2)
BCL2 inh: R/R CLL (mono, combo) and NHL Phase 1 (ASCO1)
Avastin + Tarceva: Lung Phase 2 (ASCO1)
Polatuzumab: R/R NHL Phase 2 (ASCO1)
Crenezumab: Alzheimer Phase 2 (AAIC3)
ACE 910: haemophilia Phase 1 (WFH4)Oral Octreotide:Acromegaly Phase 3 (ENDO5)
Key data read outs
1 American society of clinical oncology 2014; 2 European Association of Dermato-Oncology 2014; 3 Alzheimer's Association International Conference 2014; 4 World Federation of Hemophilia 2014; 5 Endocrine Society Meeting 2014, 6 Qualified Infectious Disease Product designation
Compound Highlight
aPDL1: bladder Breakthrough therapy designation
Avastin: cervical Priority review designation
Avastin: ovarian Priority review designation
LptD: antibiotic QIDP6 & Fast track designation
Oncology
Neuroscience
Infectious Diseases
Immunology
Other
15
HY 2014: Pharma salesUS the major growth contributor
16
HY 2014 HY 2013 Change in %CHFm CHFm CHF CER
Pharmaceuticals Division 17,834 18,162 -2 4United States 7,572 7,553 0 5
Europe 4,775 4,652 3 3
Japan 1,581 1,672 -5 7
International 3,906 4,285 -9 2
CER=Constant Exchange Rates
CER = Constant Exchange Rates (avg full year 2013) * One-off items: impacts from past service income (PSI) / filgrastim deal
9%
5%
2%
2%
4%
HY 2014: Pharma operating performanceMargin improvement driven by operating efficiency
17
Sales 17,834 100.0
Royalties & other op inc 1,334 7.5Cost of sales -3,557 -20.0M & D -2,703 -15.2R & D -3,712 -20.8G & A -595 -3.3
Core operating profit 8,601 48.2
2014 vs. 2013CER growth
HY 2014CHFm % sales
+1% in CHF
57%
45%
Excl. one-off items*: +6%
Admin: +7%Excl. PSI: +13%
Excl. MetMAb/ bito : +3%
Excl. MetMAb/ bito : 0%
Excl. filgrastimdeal: +8%
HY 2014: Pharma salesHER2, Avastin and MabThera main growth drivers
18Absolute amounts in CHFm at Constant Exchange Rates (CER) average 2013; all growth rates at CER
-300 -200 -100 0 100 200 300
Xeloda
Pegasys
CellCept
Xolair
Actemra/RoActemra
MabThera/Rituxan
Kadcyla
Herceptin
Avastin
Perjeta
USEuropeJapanInternational
+276%
+6%
+6%
+188%
+4%
+19%
+22%
-34%
-15%
-6%
HY 2014 sales: Oncology up 6%
19
CER growth
0 1 2 3 4
Zelboraf
Xeloda
Tarceva
Avastin
MabThera/Rituxan
HER2
+4%
-1%
+6%
-34%
CHFbn
-5%
Herceptin
Perjeta
Kadcyla
+20%
CER=Constant Exchange Rates Oncology HY 2014 sales: CHF 11.1bn
In-class competition
Loss of exclusivity in EU (Dec 2013) and US (March 2014)
Treatment through multiple lines Continued uptake in ovarian cancer (EU)
Strong uptake of Perjeta and Kadcyla
Competitive pressure in US Strong growth in Europe and International regions
Increased usage across a variety of indications
Avastin: Strong growth supported by treatment through multiple lines (CRC) and ovarian
Ovarian cancer in Pt resistant
• Priority review (FDA), CHMP positive opinion
Cervical cancer
• Priority review (FDA), filed in EU; Canadian reimbursement
Lung cancer
• Avastin + Tarceva well received at ASCO
Breast cancer
• Positive Phase 3 data at ESMO, IMELDA & TANIA0
600
1,200
1,800
Q2 12 Q2 13 Q2 14
CHFm
US Europe International Japan
YoY CER growth
4%
5%13%
Absolute amounts at 2013 exchange rates; growth at CER=Constant Exchange Rates20
CHFm
HER2 franchise: Fast uptake of recently launched products
21
0
500
1'000
1'500
2'000
Q112
Q212
Q312
Q412
Q113
Q213
Q313
Q413
Q114
Q214
Kadcyla
Perjeta
Herceptin
7%14% 16% 10%
15%
YoY growth1CHFm
1CER=Constant Exchange Rates
15% 20%17%
23%
7%
HER2 franchise: +20% growth1 in HY 2014
HY 2014: +20%1
Herceptin subcutaneous deliveries: Fast adoption in vast majority of countries
22
0% 20% 40% 60%
Sep
Oct
Sep
Oct
Sep
Nov
Dec
Sep
Nov
SepSweden
Denmark
UK
Chile
Finland
Austria
Norway
Portugal
Netherlands
Germany
SC share of total Herceptin salesCountry / launch
200
300
400
500
Q111
Q211
Q311
Q411
Q112
Q212
Q312
Q412
Q113
Q213
Q313
Q413
Q114
Q214
Lucentis: Medical benefit and long-term safety proven in 27 clinical trials
23AMD=wet age-related macular degeneration; RVO=retinal vein occlusion; DME=diabetic macular edema; BRVO= Branch Retinal Vein Occlusion
Lucentis quarterly sales (USDm)
EyleawAMD
LucentisDME
AMDLess-frequent than
monthly dosing
AMD and RVO
• Stable use; increasing market
• Competition in BRVO 2H 2014
DME
• Increased patient share YoY
• Potential competition 2H 2014
2014 outlook
• Benefit from the overall market growth in all indications
Actemra: Continued uptake
24
0
100
200
300
Q112
Q212
Q312
Q412
Q113
Q213
Q313
Q413
Q114
Q214
CHFm
1CER=Constant Exchange Rates
46% 32%27%
30% 32%
33% 23% 23%21%
33%
HY 2014: +22%1
SC formulation driving further growth
YoY growth1
Crenezumab: ABBY “Cognition Study” Larger effect in milder patients and high dose (IV)
26
P values are not adjusted for multiplicity
MMSE 22-26MMSE 20-26MMSE1 18-26
• Co-primary endpoints2 for overall study missed• Treatment effect in ADAS-Cog12 was observed with high dose (IV) in milder patients• Acceptable safety profile
1 MMSE: Mini-Mental State Examination; 2Primary end-point: ADAS-Cog12 and CDR-SOB, included Safety run-in cohort to test high dose; In collaboration with AC Immune
MMSE N (plc) N (active) Δ (SE) % ES (SD) p18-26 64 122 1.78 (1.35) 16.8% 0.2 (9.08) 0.19020-26 47 93 2.24 (1.47) 23.8% 0.27 (8.44) 0.12822-26 33 70 3.44 (1.61) 35.4% 0.44 (7.80) 0.03618-21 31 52 -0.15 (2.25) -1.3% -0.01 (10.38) 0.947
• 20 projects in clinic or pre-clinic
• Encouraging Phase 1 data for bladder cancer and proof of concept for anti-CSF-1R
• 9 ongoing trials, 6 new clinical trials planned in 2014: anti-OX40, anti-CD40, INO-5150, aPDL1 + Gazyva, aPDL1 + immune modulators, Phase 3 bladder
• Undisclosed cancer type
Cancer Immunotherapy
ASCO 2014: Roche/GenentechHighlights in cancer immunotherapy
27
Urothelial Bladder CancerMPDL3280A Phase 1 Data
aPDL1 IHC (n)
ORR (95% CI)
Dx+ vs Dx- ORR(95% CI)
IHC 3 (n=10) 50% (22-78)43% (26-63)
IHC 2 (n=20) 40% (21-64)
IHC 1 (n=23) 13% (4-32)11% (4-26)
IHC 0 (n=12) 8% (0.4-35)
• Avastin: Superior efficacy in EGFR+ for Avastin and Tarceva (JO25567)
• Alectinib: Highly promising data incl. durable response in brain mets
Lung Cancer
• Avastin: CALGB 80405, Cetuximabfailed to show superiority over Avastinin 1L CRC
GI Cancer
• Zelboraf and Cobimetinib:Promising combo data (BRIM7)
Skin Cancer
* In collaboration with AbbVie
• GDC-0199*: Strong data in a Phase 1b dose escalation trial
• Polatuzumab ved.: Promising results enabling late stage development (Romulus)
Hematology
ASCO 2014: HighlightsStrong data across the major oncology franchises
28
30
Q2 2014 Pipeline update on Phase 3 activity
Compound Indication
Kadcyla/Perjeta1L met. HER2+ BC(MARIANNE)
cobimetinib BRAF+ mM (coBRIM)oral octreotide acromegaly
Compound Indication
Kadcyla adjuvant BC (KAITLIN)
Kadcyla neo-adjuvant (KRISTINE)
Bcl-2 inh Rel/Ref CLL (MURANO)
aPDL1 2/3L NSCLC (OAK)
alectinib ALK+ NSCLC
etrolizumab inflammatory bowel disease
gantenerumab mild AD (Marguerite RoAD)
lampalizumab geographic atrophy
Phase 3 readouts Key Phase 3 starts
Data available
2014: Key regulatory milestones
31Outcome studies are event driven, timelines may change
Compound Indication Milestone
Actemra subcutaneous Rheumatoid arthritis EU approval
Avastin Glioblastoma EU approval
Avastin Cervical cancer US, EU filing
Avastin Pt resistant ovarian cancer EU approval
MabThera subcutaneous NHL EU approval
obinutuzumab (GA101) Front line CLL EU approval
Xolair Chronic idiopathic urticaria US approval
Planned data presentations in H2 2014
32
Madrid, 26-30 Sep
Avastin BC• HER2-BC (IMELDA)• TML HER2-mBC (TANIA)
Perjeta• (OS data) CLEOPATRA
Zelboraf + Cobimetinib1
• Phase 3 (coBRIM) (planned)
aPDL1• Oral presentations in
monotherapy and combinations
ASH
San Francisco, 6-9 Dec
Gazyva• GREEN study G + various
backbones (planned)
ACE9102
• Hemophilia (planned)
Berlin, 18-21 Oct
mGlu5• MARIGOLD study
(Phase 2 in depression)
Alecensa (alectinib)2
• Japan Phase 1/2 update
Chicago, 30 Oct -1 Nov
Avastin Lung• BEYOND study (planned)
1 In collaboration with Exelixis, 2 In collaboration with Chugai
HY 2014: Diagnostics sales Growth driven by Professional Diagnostics
34
HY 2014 HY 2013 change in %CHFm CHFm CHF CER
Diagnostics Division 5,140 5,133 0 +6Professional Diagnostics 2,904 2,825 +3 +9
Diabetes Care 1,140 1,205 -5 0
Molecular Diagnostics1 762 781 -2 +4
Tissue Diagnostics 334 322 +4 +9
1Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +6%CER=Constant Exchange Rates
North America+6%
25% of divisional sales
Latin America+11%
7% of divisional sales
Japan+4%
4% of divisional salesEMEA1
+2%
47% of divisional sales
HY 2014: Diagnostics regional sales Growth across all geographies
Asia Pacific+15%
17% of divisional sales
35
16% growth in E7 countries2
1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates
0%
36
HY 2014: DiagnosticsGrowth driven by Professional Diagnostics
FDA approval for cobas HPV test for primary screening in cervical cancer. HPV (+59%), virology (+5%) and blood screening (+7%)
Sales driven by Accu-Chek Aviva/Performa (+2%), Accu-Chek Mobile (+22%) and Insulin Delivery Systems (+6%)
Growth driven by advanced staining portfolio (+8%) and companion diagnostics (+29%)
1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +6% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa
Sales CHFbn
CER growth
1
+9%
+4%
+9%
Continued double digit growth in immunodiagnostics (+12%) Launch of cobas 6500 fully automated urinalysis system
0 1 2 3
Tissue Dia
MolecularDia
DiabetesCare
ProfessionalDia
EMEANorth AmericaRoW
HY 2014: Diagnostics DivisionProfit influenced by unfavorable base effects
2014 vs. 2013CHFm % sales CER growth
Sales 5,140 100.0
Royalties & other op inc 64 1.2Cost of sales -2,319 -45.0M & D -1,170 -22.8R & D -492 -9.6
G & A -235 -4.6
Core operating profit 988 19.2
HY 2014
18%
0%
6%
0%
10%
-10%
6%
18%
Excl. one-off item PSI*: +2%
Admin: +4%Excl. PSI: +3%
CER = Constant Exchange Rates (avg full year 2013) * One-off item: impacts from past service income (PSI) in 2013
-9% in CHF
37
RPD: Growth driven by serum work area solutionsLargest footprint and broadest menu in the industry
23%Roche
Others
Leader in CHF 19bn SWA market
cobas 8100
Integrated SWA1 solution
• 41% of Diagnostics sales in SWA (+11%):– Immunodiagnostics (+12%)– Clinical chemistry (+9%)
*Source: Roche Analysis, Company reports for 2013 validated by an independent IVD consultancy; 1SWA: serum work area (immunodiagnostics & clinical chemistry)
38
RPD: Launch of cobas 6500 for urinalysisFully automated urine testing solution
• Target market ~CHF 600m• Combines urine strip testing & digital
microscopy• 23 parameters measured to help
diagnose urinary tract infections, kidney diseases and diabetes
• Competitive advantages: – Fastest and most accurate instrument– Reagent free– Minimizes manual steps– Improves safety
cobas 6500
urine work area
39
Molecular Diagnostics: HPV testingApproval for primary screening in US and Canada
• HPV market ~CHF 300m (+13%)
• FDA recommends cobas HPV test as primary screening for cervical cancer and expand screening age to 25 - 29
• ATHENA study: Pap smear misses cervical disease in 1 in 7 HPV 16 positive women
• Ongoing pilot studies: Sweden, Netherlands, UK and Italy
Three results in one test• HPV genotype 16• HPV genotype 18• 12 high risk HPV pool
cobas HPV test (+59%) HPV primary screening
40
RMD: cobas 8800/6800/4800Setting new standards for molecular testing
Blood Screening Virology HPV & CT/NG Microbiology Genomics & Oncology
• Multiplex HIV, HCV, HBV• West Nile Virus• B19 and HAV
• HIV• Hepatitis B, C• HSV• CMV
• Human Papillomavirus
• Chlamydia & Gonorrhea
• MTBMAI• MRSA• C. Difficile
• BRAF • K-RAS• EGFR• PIK3CA
cobas 4800 SystemRMD Platform Strategy
cobas 8800/6800 Systems
RMD Assays
41
• Advanced PCR automation• Highest throughput (3x above closest competitor)• Broadest menu
• Low to middle volume throughput• Broadest menu
*Excluding US;1Business Areas: RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics,RTD: Roche Tissue Diagnostics; 2 hospital information systems; 3 blood glucose monitoring; 4 parvovirus B19 and hepatitis A virus; 5 west nile virus
Key launches 2014
42
Area Product Market BA1
Instruments/
Devices
Labs
cobas 6800/8800 – Next generation molecular (PCR) systemcobas m 511 – Fully integrated and automated hematology systemcobas 6500 – Automated urinalysis work area platformConnect-V – Middleware providing connectivity to LIS2
WW*EUEUWW
RMDRPDRPDRTD
Diabetes Care
Accu-Chek Insight- Next generation insulin pump & bGm3 systemAccu-Chek Connect – bG meter with connectivity to smart phones, mobile App and cloud
EU
EU
RDC
RDC
Tests/
Assays
Infectious Diseases /Blood Screening
MPX 2.0 – Next generation blood screening multiplex testMPX (HIV, HCV, HBV), HEV, DPX4, WNV5 – Full NAT blood screening menu for cobas 6800/8800 HIV, HCV, HBV – Virology tests for cobas 6800/8800HSV- Detection of Herpes Simplex Virus on cobas 4800Syphilis– Immunoassay for the detection of Treponema pallidum
USWW*
WW*EUEU
RMDRMD
RMDRMDRPD
MicrobiologyMRSA/SA – Next generation assay on cobas 4800C-difficile – Diagnosis of infections and associated diarrhea
EUEU
RMDRMD
Women’s Health
PE Prognosis- Claim extension for short-term prediction of Preeclampsia in pregnancyAMH- Assessment of ovarian reserve for fertility
EUEU
RPDRPD
HY 2014: Finance highlights
44
Business
• Strong Core EPS growth: +7%1
• Free cash flow +41% better1
• Accounts receivable in Southern Europe further decreased
Improved financial result
• Positive development of Core Net Financial result: +17%1 lower expense• Early bond call of USD 0.5bn with CHF 80m costs
1 At constant exchange rates
Sales 22,974 23,295 -1 +5Core operating profit 9,410 9,488 -1 +7
as % of sales 41.0 40.7Core net income 6,641 6,649 0 +8
as % of sales 28.9 28.5Attributable to Roche shareholders 6,533 6,542 0 +8
Core EPS (CHF) 7.57 7.58 0 +7
Operating free cash flow 7,869 7,445 +6 +11% of sales 34.3 32.0
Free cash flow -1,026 -1,392 -26 -41% of sales -4.5 -6.0
HY 2014: Group performance Core EPS growth +7%1, Free cash flow 41% better
46
CHFmHY 2014 HY 2013 CHF CER
1 CER=Constant Exchange Rates
% Change
2014: Impact on core profit from one-off items
47
H1 H2
in CHFm Group Pharma Dia Corporate Group Pharma Dia Corporate
Sale of filgrastim rights(2014) 428 428
Core op. profit related to filgrastim revenue (2013) -61 -61 -61 -61
Past service income (2013) -252 -121 -28 -103 -50 -10 -39 -1
340B reserves release (2013) -145 -145
Operating profit 115 246 -28 -103 -256 -216 -39 -1
Deferred taxes -25 78
Net income 90 -178
HY 2014: Group operating performanceGood sales momentum translated into profit increase
48
7%
5%
2%
5%
5%
2014 vs. 2013CER growth
-1% in CHF
COGS & PC1: +6%
Sales 22,974 100.0
Royalties & other op inc 1,398 6.1Cost of sales -5,876 -25.5M & D -3,873 -16.9R & D -4,204 -18.3G & A -1,009 -4.4
Core operating profit 9,410 41.0
HY 2014CHFm % sales
52%
39%
Excl. one-off items*: +6%
CER = Constant Exchange Rates (avg full year 2013) 1 Cost of goods sold & period cost * One-off items: impacts from past service income (PSI) / filgrastim deal
Admin: +4%Excl. PSI: +4%
Excl. MetMAb/ bito : +4%
Excl. MetMAb/ bito : +4%
Excl. filgrastimdeal: +7%
38.5% 40.7% 41.0% 45.3% 46.9% 48.2%
19.9%
21.1%
19.2%
HY 2014: Core operating profit and margin continuously increasing at Group level
49
CHFm
% of sales+1.0 %p1
(+0.3 %p)
-1.2 %p1
(-1.9 %p)
+2.0 %p1
(+1.3 %p)
0 %1
(-9 %)
+9 %1
(+1 %)
+7 %1
(-1 %)
1 CER=Constant Exchange Rates
8'6417'889
998
9'4888'522
1'083
9'4108'601
988
Roche Group Pharma Division Diagnostics Division
2013 20142012
-838 -838
-776-721
-669-658 -658
-48+110
+55 +52 +11
-1'000
-800
-600
-400
-200
0
HY 2014: Core net financial result further improved
50
FX G/LHY 2013 HY 2014Net income from equity securities
Interestexpense
CER=Constant Exchange Rates
All other,net
Debt redemption
Improvement of 21% in CHF / 17% at CER
CHFm
23.124.1
-0.4+1.4
Column1 Non-US US HY 2014
HY 2014: Group core tax rateHigher tax rate due to US R&D tax credits in 2013
51
in %
Mainly impact from the mix of
core profit before tax
US Federal R&D tax credits for both
2012 and 2013, booked in H1 2013
HY 2013 HY 2014
14%
Net debt/ total assets:
Assets Equity & liabilities
33.0 34.021.2 19.5
17.3 17.7
25.2 24.6
11.9 10.3 15.8 17.9
31/12/13 30/06/14 31/12/13 30/06/14
62.0 62.00%
-14%
+3%
+3%
Current liabilities
Non-current liabilities
Equity (Net assets)
19% 17%
28%
53%
29%
34% 31%
62.2 62.2
% change in CER vs 31/12/13
Current liabilities
Non-current liabilities
Equity (Net assets)
54%
25%
41%
29%
40%
+14%
% change in CER vs 31/12/13
0%
-2%
-9%
Cash and marketable securities
Other current assets
Non-current assets
CHFbn
Balance sheet: Equity ratio 31%
Net debt/ total assets
14%
CER = Constant Exchange Rates (avg full year 2013)52
7'2446'699
805
7'4457'024
700
7'8697'424
632Roche Group Pharma Division Diagnostics Division
32.3% 32.0%34.3%
38.5% 38.7%41.6%
16.1%13.6% 12.3%
HY 2014: Operating free cash flow and margin further increased
CHFm
% of sales
+2.0 %p1
(+2.3 %p)
-0.4 %p1
(-1.3 %p)
+2.2 %p1
(+2.9 %p)
+3 %1
(-10 %)
+10 %1
(+6 %)
+11 %1
(+6 %)
2013 20142012
1 CER=Constant Exchange Rates54
B-
BB
BB
BB
BB
-
CHFm
Sovereign country ratings from Standard & Poor’s, as of 3 Jul 2014 1 At constant exchange rates 30 Jun 2014 vs. 31 Dec 2011
2'462
1'036
980
209
236
1'836
604
819
163
251
1'645
613
733
114
185
1'394
467
590
143
193
0 400 800 1'200 1'600 2'000 2'400 2'800
SouthernEuropeanCountries
Spain
Italy
Portugal
GreeceJun 2014
Dec 2013
Dec 2012
Dec 2011
-43%1
Accounts receivable in Southern EuropeRisk exposure constantly reduced
55
0
1
2
3
4
2014 2015 2016 2017 2018 2019 2021 2022 2023 2035 2039
USD EUR CHF GBP
HY 2014: Debt maturity profile71% of Genentech related debt repaid
56Nominal values @ actual FX rates; *Original net proceeds in CHF
Of the CHF 48 bn bonds and notes issued to finance the Genentech transaction, cumulative CHF 34 bn have been repaid as of June 30, 2014*
CHF bn
Repayment USD 1.0 bn
Call of GBP 0.42 bn Early bond call in
Q3 2014 (0.5bn)
-6.7+7.9 -8.8
-8.9
-1.1
CHFbn
HY 2014: Group net debt slightly increased due to dividend payments in H1 2014
0
Net debt31 Dec 13
Operating FreeCash Flow
Currency translation, transaction in own equity instruments
& others
Net debt30 Jun 14
Dividends -6.7Taxes -1.5Treasury -0.7
Non-op.FCF
Roche Pharma 7.1Chugai 0.3Diagnostics 0.5Diabetes Care 0.2Other -0.2
Free Cash Flow CHF -1.0bnoutflow 41% (CER) lower than HY 2013
57
Own Equities -0.6Business Comb -0.4Other -0.1
Strong earnings capacity reflected in sustained net debt reduction
58
Net debt(CHFbn)
Total assets(CHFbn)
Net debt /total assets
8.8
62.0
30 Jun 2012 31 Dec 2012 30 Jun 2013 31 Dec 2013 30 Jun 2014
29%
16%
23%
11%14%
Currency impact on Swiss Franc results 2014Negative currency impact expected
Q1 HY Sep YTD
FY
Sales -6 -6 -5 -4
Core operating profit
-8 -6
Core EPS -8 -6
Assuming the 30 June 2014 exchange rates remain stable until end of 2014, 2014 impact is expected to be (%):
CHF / USD
CHF / EUR
+1%+1%
+2% +2%
0.90 0.89 0.88 0.89 0.900.88 0.89 0.89 0.890.89 0.89 0.89
0.890.89 0.89 0.89
0.930.94 0.930.93
J F M A M J J A S O N D
1.23 1.22 1.22 1.22 1.22 1.22 1.221.221.22 1.221.221.22
1.231.23 1.231.23
1.22
1.221.22
1.22
J F M A M J J A S O N D
Average YTD 2013
-4%-5% -5% -4%
0% -1% -1% -1%
Assumed average YTD 2014
Monthly avg fx rates 2014 Fx rates at 30 June 2014
59
2014 Outlook
601At constant exchange rates
Group sales growth1 Low- to mid-single digit
Core EPS growth1 Ahead of sales growth
Dividend outlook Further increase dividend
6262
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
Changes to the development pipelineHY 2014 update
New to Phase I New to Phase II New to Phase III New to Registration3 NMEs added by pREDRG7342 mGlu5 PAMschizophrenia RG7775 MDM2 (4) antagonist IV prodrug AMLRG7935 a-synuclein MAbParkinson's Disease 1 NME added by gREDRG7882 ADC - ovarian cancer
4 NMEs moved from phase 1RG1662 GABRA5 NAM - Down syndromeRG7155 CSF-1R MAb - PVNSRG7604 taselisib (PI3k beta sparing) –solid tumorsRG7221 Ang2-VEGF MAb - colorectal cancer1 AI RG7601 Bcl-2 inh – DLBCLNME ACE910 shown as RG6013FIXA/FX bispecific MAb – hemophiliaA (inlicensed from Chugai)
1 NME moved from phase 2RG7413 etrolizumab - ulcerative colitis1 Chugai NME moved from phase 1IL6R MAb in neuromyelitis optica
2 AIsRG3502 Kadcyla + Perjeta HER2-positive BC adjuvantRG3502 Kadcyla + Perjeta HER2-positive BC neoadjuvant
1 AI following EU/US submissionRG435 Avastin – recurrent cervical cancer
Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration1 AI RG3638 onartuzumab – liver cancer2 NMEsRG7863 TLR7 agonist (2) - HBVRG7598 ADC - multiple myeloma1 NME terminated by Roche and ChugaiRG7167 MEK inh - solid tumors
1 AI RG3638 onartuzumab - mCRC 1st line2 NMEsRG7415 rontalizumab – systemic lupus erythematosusRG7652 PCSK9 MAb - metabolic diseases
2 NMEsRG3638 onartuzumab - gastric cancerRG3806 oral octreotide -acromegaly2 AIsRG435 Avastin - HER2-neg. BC adjuvantRG435 Avastin - high risk carcinoid
1 AI following EU ApprovalRG1569 Actemra - RA sc formulation
Status as of July 24, 2014
63
Phase I (28 NMEs + 8 AIs)
Raf & MEK dual inh solid tumorsRG7304
Bcl-2 inh heme indicationsRG7601
ChK1 inh solid tum & lymphomaRG7741
Oncology Other disease areas
Status as of July 24, 2014
HER3 MAb solid tumorsRG7116
MDM2 ant solid & hem tumorsRG7388
ADC Mesothelin ADC pancreatic caRG7600
Roche Group development pipeline
64
ETBR ADC metastatic melanomaRG7636PI3k inh glioblastoma 2L RG7666 New Molecular Entity (NME)
Additional Indication (AI)
OncologyImmunologyInfectious DiseasesCardioMetabolismNeuroscienceOphthalmologyOther
RG-No Roche Genentech managedCHU Chugai managed
PD-L1 MAb+Zelboraf m. melanoma RG7446
Steap 1 ADC prostate ca.RG7450MUC16 ADC ovarian & pancreatic ca.RG7458
PD-L1 MAb+Avastin+chemo solid tumors RG7446
PD-L1 MAb solid tumorsRG7446PD-L1 MAb+cobimetinib solid tumors RG7446
Bcl-2 inh + Gazyva CLLRG7601
PD-L1 MAb+Tarceva NSCLC EGFR+RG7446
PI3K inh solid tumorsCHU
ERK inh solid tumorsRG7842
CEA IL2v solid tumorsRG7813
- heme tumorsRG7845
GIP/GLP-1 dual ago type 2 diabetesRG7697
IL-17 MAb autoimmune diseases RG7624TLR7 agonist HBVRG7795
Lucentis sust. deliv. AMD/RVO/DMERG3645
PDE10A inh schizophrenia RG7203
SMN2 splicer spinal muscular atrophy RG7800
aldosterone synth inh kidney disease RG7641
VEGF-ANG2 MAb wAMD RG7716
TAAR1 ago schizophrenia RG7410
LSD1 inh AMLRG6016
URAT 1 inh goutCHU
ADC solid tumorsRG7841
MDM2 (4) IV prodrug AMLRG7775
a-synuclein MAb Parkinson's DiseaseRG7935
mGlu5 PAM schizophreniaRG7342
ADC ovarian caRG7882
New Molecular Entity (NME) Additional Indication (AI)
RG-No Roche Genentech managedCHU Chugai managedRG105 MabThera is branded as
Rituxan in US and JapanRG1569 Actemra is branded as
RoActemra in EURG7159 Gazyva is branded as Gazyvaro in EU
OncologyImmunologyInfectious DiseasesCardioMetabolismNeuroscienceOphthalmologyOther
Roche Group development pipelinePhase II
(29 NMEs + 8 Als)Phase III
(8 NMEs + 18 Als)Registration
(1 NME + 4 Als)
1 US only: FDA submission decision pending2 Submitted in EU, US filing pending3 Approved in US, submitted in EU4 Submitted in EU
Avastin glioblastoma 1st lineRG4352
Gazyvaro (obinutuzumab) CLLRG71593
Perjeta HER2+ BC adj RG1273
Avastin ovarian cancer 1st lineRG4351
Avastin NSCLC adjRG435
bitopertin obsessive compulsive dis.RG1678
Kadcyla +/- Perjeta HER2+ mBC 1st lRG3502
ocrelizumab RMSRG1594
Gazyva (obinutuzumab) DLBCLRG7159
ocrelizumab PPMSRG1594
Suvenyl enthesopathyCHU
lebrikizumab severe asthmaRG3637
Avastin rel. ovarian ca. Pt-resistantRG435
Kadcyla HER2+ BC adjRG3502
Zelboraf m. melanoma adjRG7204cobimetinib + Zelboraf m. melanomaRG7421
Avastin rel. ovarian ca. Pt-sensitiveRG4351
Perjeta HER2+ gastric cancerRG1273Actemra early RA RG15694
Actemra giant cell arteritisRG1569
mericitabine HCVRG7128danoprevir HCVRG7227
basimglurant (mGlu5 NAM) TRDRG7090
quilizumab asthmaRG7449etrolizumab ulcerative colitisRG7413
crenezumab Alzheimer’sRG7412
MAO-B inh Alzheimer’s RG1577decoglurant (mGlu2 NAM ) depressionRG1578
pictilisib pictilisib (PI3K inh) solid tumorsRG7321
Actemra systemic sclerosisRG1569
HER3/EGFR MAb m. epithelial tumorsRG7597
pinatuzumab vedotin (CD22 ADC) hem tumorsRG7593polatuzumab vedotin (CD79bADC) hem tumorsRG7596
CMV MAb CMV RG7667
lampalizumab (factor D) geo. atrophyRG7417
Perjeta HER2+ mBC 2nd lineRG1273
alectinib (ALK inhibitor) NSCLCRG7853
Gazyva (obinutuzumab) iNHL relapsedRG7159Gazyva (obinutuzumab) iNHL front-lineRG7159
V1 receptor antag autism RG7314
ipatasertib (AKT inh) solid tumorsRG7440
Erivedge AMLRG3616 Avastin recurrent cervical cancerRG435
lebrikizumab idiopathic pulmonary fibrosisRG3637
LptD antibiotic antibacterialRG7929
Bcl-2 inh CLL rel/refractRG7601
Kadcyla HER2+ gastric cancerRG3502
Bcl-2 inh CLL rel/refract 17pdelRG7601
PD-L1 MAb bladder cancerRG7446
gantenerumab Alzheimer’sRG1450Flu A MAb influenzaRG7745
IL-31R MAb atopic dermatitis CHU
FIXa /FX FIXa /FX bispecific MAb hemophilia ARG6013
PD-L1 MAb NSCLC 2nd lineRG7446
PD-L1 MAb NSCLC 2nd/3rd lineRG7446
GABRA5 NAM Down SyndromeRG1662
ADC NaPi2b ADC Pt-resistant ovarian cancerRG7599
PD-L1 MAb + Avastin RCCRG7446
CSF-1R MAb PVNS RG7155
taselisib (PI3K inh beta sparing) solid tumorsRG7604Bcl-2 inh DLBCLRG7601
Ang2-VEGF MAb colorectal cancer RG7221
Kadcyla + Perjeta HER2+ BC adjRG3502Kadcyla + Perjeta HER2+ BC neoadjRG3502
inclacumab ACS/CVDRG1512
setrobuvir HCVRG7790
glypican-3 MAb liver cancerRG7686
IL-6R MAb neuromyelitis opticaCHU
Status as of July 24, 2014
NME submissions and their additional indicationsProjects currently in phase 2 and 3
66Unless stated otherwise, submissions are planned to occur in US and EU* lead market China Neuroscience
OphthalmologyOtherNME
OncologyImmunologyInfectious DiseasesCardioMetabolism
bitopertin (RG1678)obsessive compulsive dis.
ocrelizumab (RG1594)PPMS and RMS
cobimetinib (MEK inh)combo Zelboraf
met melanoma
mericitabine (RG7128)HCV
danoprevir* (RG7227) HCV
pictilisib PI3K inh(RG7321) solid tumors
basimglurant (RG7090)depression
crenezumab (RG7412)Alzheimer‘s
gantenerumab (RG1450)Alzheimer‘s
V1 receptor antag (RG7314)autism
decoglurant (RG1578)depression
HER3/EGFR MAb (RG7597)m. epithelial tumors
glypican-3 MAb(RG7686)liver cancer
quilizumab (RG7449) asthma
lampalizumab anti-factor D(RG7417) geo atrophy
lebrikizumab (RG3637) severe asthma
etrolizumab (RG7413) ulcerative colitis
2014 2015 2017 and beyond
CMV MAb (RG7667)CMV
pinatuzumab vedotin, RG7593 CD22 ADC heme tumors
alectinib ALK inh(RG7853) NSCLC
PD-L1 MAb (RG7446) NSCLC 2nd/3rd line
Bcl-2 inh (RG7601)CLL rel/refract
ipatasertib AKT inh(RG7440) solid tumors
MAO-B inh (RG1577)Alzheimer‘s
polatuzumab vedotin, RG7596CD79b ADC heme tumors
LptD antibiotic (RG7929)antibacterial
lebrikizumab (RG3637) idiopathic pulmonary fibrosis
2016
PDL-1 MAb (RG7446)combo Avastin RCC
Flu A MAb (RG7745)influenza
taselisib PI3K inh β-sparing(RG7604) solid tumors
Status as of July 24, 2014
GABRA5 NAM (RG1662)Down syndrome
NaPi2b ADC (RG7599)Pt-resistant ovarian cancer
PDL-1 MAb (RG7446)bladder cancer
CSF-1R MAb (RG 7155)solid tumors & PVNS
Bcl-2 inh (RG7601)DLBCL
Ang2-VEGF MAb (RG7221)colorectal cancer CRC
FIXa /FX bispecific MAb (RG6013) hemophilia A
AvastinNSCLC adj
2014 2015 2017 and beyond
*Avastin (US) ovarian cancer 1st line
Indicates submission to health authorities has occurred.* Approved in the EUUnless stated otherwise, submissions are planned to occur in US and EU.
*Avastin (US)rel. ovarian ca. Pt-sens
Submissions of additional indications for existing productsProjects currently in phase 2 and 3
67Status as of July 24, 2014
Actemrasystemic sclerosis
Perjeta HER2-pos. BC adj
Perjeta
HER2-pos. gastric cancer
Zelborafmet. melanoma adj.
Kadcyla +/- PerjetaHER2-pos mBC 1st line
KadcylaHER2-pos gastric cancer
KadcylaHER2-pos. early BC
Avastincervical cancer recurrent
Actemragiant cell arteritis
ErivedgeAML
2016
Avastin (US)rel. ovarian ca. Pt-resist
Avastin (US)glioblastoma 1st line
Gazyva DLBCL
Gazyva iNHL relapsed
Gazyva frontline NHL
NeuroscienceOphthalmologyOtherNME
OncologyImmunologyInfectious DiseasesCardioMetabolism
Perjeta
HER2-pos. mBC 2ndline
Major granted and pending approvals 2014
68Status as of July 24, 2014
EU
US
Approved Pending approvals
MabTheraNHL sc formulation
March 2014
ActemraRA sc formulation
April 2014
Avastinglioblastoma 1st line
Filed March 2013
Xolairchronic idiopathic urticaria
March 2014
Avastin*rel. ovarian ca. Pt-resistFiled September 2013
Actemraearly RA
Filed Jun 2013
Gazyvaro* CLL
Filed April 2013
*CHMP pos.opinion
Avastincervical cancerFiled April 2014
Avastincervical cancerFiled June 2014
Avastinrel. ovarian ca. Pt-resist
Filed May 2014
alectinib ALECENSAALK-pos rec/adv NSCLC
July 2014
Zelborafm. melanoma
Filed April 2014Japan-Chugai
NeuroscienceOphthalmologyOtherNME
OncologyImmunologyInfectious DiseasesCardioMetabolism
6969
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
70
Patient population
Front-line metastatic ovarian cancer
Phase/study Phase III GOG-0218
Phase III ICON7
# of patients N=1,873 N=1,528
Design ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months)
ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months)
ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months)
ARM A: Paclitaxel and carboplatin for 6 cycles ARM B: Paclitaxel and carboplatin plus concurrent Avastin for
6 cycles followed by Avastin alone for up to 18 cycles (12 months)
Avastin dose 15 mg/kg q3 weeks 7.5 mg/kg q3 weeks
Primary endpoint
Progression-free survival Progression-free survival
Status Study met its primary endpoint in Q1 2010 Data presented at ASCO 2010 and 2011 Results: NEJM 2011 Dec 29;365(26):2484-96
Study met its primary endpoint Q3 2010 Data presented at ESMO 2010 and ASCO 2011 Results: NEJM 2011 Dec 29;365(26):2473-83 OS data presented at ECC 2013
EMA approval Q4 2011 Re-evaluate FDA submission in 2014
ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology
AvastinOvarian cancer clinical development programme
71
Patient population
Relapsed Platinum-sensitive ovarian cancer
Relapsed Platinum-resistantovarian cancer
Phase/study Phase IIIOCEANS
Phase IIIAURELIA
# of patients N=484 N=361
Design ARM A: Carboplatin, gemcitabine, and concurrent placebo for 6-10 cycles, followed by placebo alone until disease progression
ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression.
ARM A: Paclitaxel, topotecan or liposomal doxorubicin
ARM B: Paclitaxel, topotecan or liposomal doxorubicin plus Avastin
Avastin dose 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks
Primary endpoint
Progression-free survival Progression-free survival
Status Study met its primary endpoint Q1 2011 Data presented at ASCO 2011 EMA approval received Q4 2012 Re-evaluate FDA submission in 2014
Study met its primary endpoint Q2 2012 Data presented at ASCO 2012 Results published in JCO 2014 May 1;32(13):1309-
16 Filed in EU Q3 2013 CHMP positive opinion Q2 2014 Filed with the FDA Q2 2014 FDA priority review granted July 2014
ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress
AvastinOvarian cancer clinical development programme
72
Patient population Stage IVB, recurrent or persistent cervical cancer
Phase/study Phase IIIGOG-240
# of patients N=452
Design ARM A: Paclitaxel, cisplatin ARM B: Paclitaxel, cisplatin plus Avastin ARM C: Paclitaxel, topotecan ARM D: Paclitaxel, topotecan plus Avastin
Avastin dose 15 mg/kg q3 weeks
Primary endpoint
Progression-free survival
Status Study met its primary endpoint Q1 2013 Results published in NEJM Feb. 2014; 370(8):734-43 Filed globally Q2 2014 FDA Priority Review granted July 2014
AvastinCervical cancer clinical development programme
Patient population High risk carcinoid Newly diagnosed glioblastoma First-line HER2-negative
metastatic breast cancer
Phase/study Phase IIISWOG SO518
Phase IIIAVAglio
Phase IIIMERiDiAN
# of patients N=424 N=920 N=480
Design ARM A: Depot octreotide plus interferon alpha
ARM B: Depot octreotide plus Avastin
ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression
ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression
ARM A: Paclitaxel + Avastin ARM B: Paclitaxel + Placebo
Avastin dose 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks 10 mg/kg q2 weeks
Primary endpoint
Progression-free survival Progression-free survival Overall survival
PFS in ITT PFS in patients with high plasma
VEGF-A
Status Recruitment completed Stopped at interim due to futility
Q2 2014
Co-primary endpoint of PFS met Q3 2012 Overall survival data presented at ASCO 2013 Filed in EU Q1 2013 Negative CHMP opinion Q2 2014 Re-examination ongoing
FPI Q3 2012 Expect data in 2015
73TMZ=temozolomideASCO=American Society of Clinical Oncology
AvastinHigh risk carcinoid, brain and breast cancer development programmes
74
Patient population
Adjuvant lung cancer
Adjuvant breast cancer
Phase/study Phase IIIECOG 1505
Phase IIIECOG 5103
HER2-negative
# of patients N=1,500 N=4,950
Design ARM A: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed
ARM B: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months
ARM A: Anthracycline plus cyclophosphamide (AC) followed by paclitaxel
ARM B: AC plus Avastin followed by paclitaxel plus Avastin
ARM C: AC plus Avastin followed by paclitaxel plus Avastin, followed by Avastin up to 12 months
Avastin dose
15 mg/kg q3 weeks 15 mg/kg q3 weeks
Primary endpoint Overall survival Disease-free survival
Status Recruitment completed Q4 2013 Expect data in 2016
Primary endpoint not met Q2 2014 Data presented at ASCO 2014
AvastinAdjuvant clinical development programme
ErivedgeA novel small molecule inhibitor of the hedgehog signaling pathway
75In collaboration with Curis
Patient population
Locally advanced or metastatic basal cell carcinoma
Acute myelogenous leukemia and relapsed refractory high-risk
myelodysplastic syndrome
Phase/study Phase IISTEVIE Phase II
# of patients N=1,200 N=60
Design Single ARM: 150 mg Erivedge orally once daily
ARM A: 150mg Erivedge orally once daily
ARM B: Cytarabine
Primary endpoint
Safety: Incidence of adverse events Overall response rate
Status FPI Q2 2011 FPI Q3 2013
GazyvaType II, glycoengineered anti-CD20 monoclonal antibody
76
Patient population
Front-line chronic lymphocytic leukaemia
Patients with comorbidities
Previously untreated or relapsed/refractory chronic lymphocytic
CLL
Phase/study Phase IIICLL11
Phase IIIGREEN
# of patients N=781 N=800
Design ARM A: Gazyva 1000mg iv plus chlorambucil
ARM B: MabThera/Rituxan plus chlorambucil
ARM C: Chlorambucil alone
Single-arm cohort study: Gazyva alone or in combination with different chemotherapy regimens (FC, Bendamustinor Clb)
Primary endpoint
Progression-free survival Safety in combination with different chemotherapy regimens
Status Filed globally Q2 2013 FDA approval granted Q4 2013 Positive CHMP opinion Q2 2014 Full data published NEJM Mar 2014;
370(12):1101-10
FPI Q4 2013
In collaboration with Biogen Idec
77In collaboration with Biogen IdecCHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone
Patient population
Diffuse large B-cell lymphoma (DLBCL)
Indolent non-Hodgkin’s lymphoma
MabThera/Rituxan refractory
Front-line indolent non-Hodgkin’s lymphoma
Phase/study Phase IIIGOYA
Phase IIIGADOLIN
Induction and maintenance study
Phase IIIGALLIUM
Induction and maintenance study
# of patients N=1,400 N=410 N=1,400
Design ARM A: Gazyva 1000mg iv plus CHOP
ARM B: MabThera/Rituxan plus CHOP
ARM A: Gazyva 1000mg iv plus bendamustine followed by Gazyvamainteinance
ARM B: bendamustine
ARM A: Gazyva 1000mg iv plus chemotherapy followed by Gazyvamaintenance
ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance
Chemotherapy: For follicular lymphoma: CHOP, CVP
or bendamustine For non-follicular lymphoma:
physician’s choice
Primary endpoint
Progression-free survival Progression-free survival Progression-free survival
Status Recruitment completed Q2 2014 Expect data in 2015
FPI Q2 2010 Expect data in 2017
Recruitment completed Expect data in 2017
GazyvaType II, glycoengineered anti-CD20 monoclonal antibody
KadcylaEvaluating new treatment options in HER2-positive early breast cancer
78In collaboration with ImmunoGen, Inc.
Patient population
HER2-positive neoadjuvantbreast cancer
HER2-positive early breast cancer high-risk patients
Operable HER2-positive early breast cancer
Phase/study Phase IIIKRISTINE
Phase IIIKATHERINE
Phase IIIKAITLIN
# of patients N=432 N=1,484 N=2,500
Design Before surgery patients will receive 6 cycles of: ARM A: Herceptin plus Perjeta
plus docetaxel plus carboplatin ARM B: Kadcyla plus Perjeta
After surgery patients will receive: ARM A: Herceptin plus Perjeta ARM B: Kadcyla plus Perjeta
ARM A: Kadcyla 3.6mg/kg q3w ARM B: Herceptin
Following surgery and antracycline-based therapy:
ARM A: Herceptin 6mg/kg q3w plus Perjeta 420 mg/kg q3w plus taxane
ARM B: Kadcyla 3.6mg/kg q3w plus Perjeta 420mg/kg q3w
Primary endpoint
Pathologic Complete Response (pCR)
Invasive disease-free survival (IDFS)
Invasive disease-free survival (IDFS)
Status FPI Q2 2014 FPI Q1 2013 FPI Q1 2014
79In collaboration with ImmunoGen, Inc.
Patient population
Previously untreatedHER2 pos. metastatic breast
cancer
Previously Treated Locally Advanced Or Metastatic Her2-
Positive Gastric Cancer
Phase/study Phase IIIMARIANNE
Phase II/IIIGATSBY
# of patients N=1,092 N=412
Design ARM A: Herceptin plus taxane ARM B: Kadcyla 3.6mg/kg q3w plus
Perjeta ARM C: Kadcyla 3.6 mg/kg q3w
plus placebo
ARM A: Kadcyla 3.6mg/kg q3w ARM B: Kadcyla 2.4mg/kg weekly ARM C: Docetaxel or paclitaxel
Primary endpoint
Progression-free survival assessed by IRF
Phase II: Dose-finding Phase III: Overall survival
Status Recruitment completed Q2 2012 Expect data in 2014
FPI Q3 2012
KadcylaEvaluating new treatment options in HER2-positive breast and gastric cancer
80
Patient population Previously untreated chronic lymphocytic leukemia
Phase/study
Phase IbSAWYER
Subcutaneous studyStudy being conducted ex-US
# of patients N=225
Design Two-stage design:- Stage 1 (dose-finding, N=55)
- Stage 2 (N=170): CLL dose confirmation: ARM A: MabThera iv plus chemotherapy
(fludarabine and cyclophosphamide) ARM B: MabThera 1600mg sc plus chemotherapy (fludarabine and
cyclophosphamide)
Primary endpoint
Part 1: PK (dose selection) Part 2: PK of MabThera iv versus MabThera sc
(arm A vs arm B)
Status FPI (stage 2) Q3 2012 Stage 1 data presented at ASH 2012
Subcutaneous MabThera : applies Enhanze technology, partnered with HalozymeASH=American Society of Hematology.
MabThera/RituxanOncology development programme
PerjetaFirst in a new class of HER dimerization inhibitors
81
Patient population Neoadjuvant HER2-positive breast cancer Adjuvant HER2-positive breast
cancer
Phase/ study Phase IINEOSPHERE
Phase IITRYPHAENA
Phase IIIAPHINITY
# of patients N=417 N=225 N=4,803
Design ARM A: Herceptin plus docetaxel ARM B: Perjeta (840mg loading,
420mg q3w) plus Herceptin and docetaxel
ARM C: Perjeta plus Herceptin ARM D: Perjeta plus docetaxel
ARM A: FEC followed by Taxane with Herceptin and pertuzumab(H+P given concurrently)
ARM B: FEC followed by Taxane with Herceptin + pertuzumab (H+P given sequentially)
ARM C: TCH + pertuzumab (H+P given concurrently)
ARM A: Perjeta (840mg loading, 420 q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles)
ARM B: Placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles)
Primary endpoint
Pathologic complete response (pCR)
Safety Invasive disease-free survival (IDFS)
Status Positive data presented at SABCS 2010
Biomarker data presented SABCS 2011
Positive safety and efficacy data presented at SABCS 2011
Recruitment completed Q3 2013 Expect data in 2016
Filed in US Q2 2013 FDA approval granted Q3 2013 EU submission in preparation
FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; SABCS=San Antonio Breast Cancer Symposium.
PerjetaFirst in a new class of HER dimerization inhibitors
82
Patient population
Second-line HER2-positive metastatic
breast cancer
Advanced HER2-positive gastric cancer
Neoadjuvant/adjuvant HER2-positive breast cancer
Phase/ study
Phase IIIPHEREXA
Phase IIIJACOB
Phase IIBERENICE
# of patients N=450 N=780 N=780
Design ARM A: Herceptin plus Xeloda
ARM B: Perjeta plus Herceptin and Xeloda
ARM A: Perjeta (840mg loading, 420mg q3w) plus Herceptin and chemotherapy
ARM B: Placebo plus Herceptin and chemotherapy
Neoadjuvant treatment: ARM A: ddAC q2w x4 cycles followed by
weekly paclitaxel for 12 weeks, with P+H x4 cycles
ARM B: FEC+P+H x4 cycles followed by docetaxel+P+H x4 cycles
Adjuvant treatment: P+H q3w to complete 1 year of HER2 t
herapy Hormonal and radiation therapy as indicated
Primary endpoint
Progression-free survival Overall survival Safety
Status Recruitment completed Q3 2013
Expect data in 2015
FPI Q2 2013 FPI expected Q3 2014
ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide;
ZelborafA selective novel small molecule that inhibits mutant BRAF
83In collaboration with Plexxikon, a member of Daiichi Sankyo GroupSee also combinations with: cobimetinib (MEK inhibitor) and anti-PDL1 (RG7446)
Patient population
Adjuvant therapy in patients with resected cutaneous BRAF mutation positive melanoma
Phase/study Phase IIIBRIM8
# of patients N=725
Design 52-week treatment ARM A: Zelboraf 960mg bid ARM B: Placebo
Primary endpoint
Disease-free survival
Status FPI Q3 2012
84
Patient population
Early moderate-to-severe rheumatoid arthritis
Moderate-to-severe rheumatoid arthritis
Moderate-to-severe rheumatoid arthritis
Phase/study Phase IIIFUNCTION
Phase IIISUMMACTA
Subcutaneous study
Pivotal Phase IIIBREVACTA
Subcutaneous study
# of patients N=1,162 N=1,262 N=656
Design 104 week treatment ARM A: Actemra IV 8 mg/kg q4w
plus placebo MTX ARM B: Actemra IV 8 mg/kg q4w
plus MTX ARM C: Actemra IV 4 mg/kg q4w
plus MTX ARM D: MTX alone
Add-on to DMARD therapy Weekly dosing for 104 weeks ARM A: Actemra SC 162mg weekly
plus placebo IV q4w ARM B: Actemra IV 8mg/kg q4w
plus placebo SC weekly
Add-on to DMARD therapy Dosing every two weeks for 104
weeks ARM A: Actemra SC 162mg q2w ARM B: Placebo SC q2w
Primary endpoint
DAS28 remission at 24 weeks, 1 year and 2 years
ACR 20 at week 24 ACR 20 at week 24
Status Primary endpoint met Q3 2012 Data presented at EULAR 2013 Filed in EU Q3 2013
Primary endpoint met Q2 2012 Presented at ACR 2012 Filed in US and EU in Q4 2012
Primary endpoint met Q3 2012 Presented at ACR 2012 Filed in US and EU in Q4 2012
FDA approval received Q4 2013 Approved in EU Q2 2014
In collaboration with ChugaiMTX=methotrexate; DMARD=Disease-Modifying Anti-Rheumatic DrugsEULAR=The European League Against Rheumatism, ACR=American College of Rheumatology
Actemra/RoActemra Interleukin 6 receptor inhibitor
85
Patient population Systemic sclerosis Giant Cell Arteritis
Phase/studyPhase II
faSScinateProof-of-concept study
Phase IIIGiACTA
# of patients N=86 N=250
Design Blinded 48-week treatment with weekly dosing: ARM A: Actemra SC 162mg ARM B: Placebo SC
Open-label weekly dosing at weeks 49 to 96: Actemra SC 162mg
Part 1: 52-week blinded period ARM A: Actemra SC 162mg qw + 26 weeks
prednisone taper ARM B: Actemra SC 162mg q2w + 26 weeks
prednisone taper ARM C: Placebo+ 26 weeks prednisone taper ARM D: Placebo+ 52 weeks prednisone taper
Part II: 104-weel open label extension – patients in remission
followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw
Primary endpoint
Change in modified Rodnan skin score (mRSS) at week 24
Safety
Proportion of patients in sustained remission at week 52
Status Primary endpoint not met, trend with improved efficacy with longer treatment observed
Adboard to advise on phase 3 held in June 2014 Study is ongoing in a blinded manner to week 48
FPI Q3 2013
In collaboration with Chugai
Actemra/RoActemraInterleukin 6 receptor inhibitor
8686
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
Alectinib (ALK inhibitor, RG7853, AF802)New brain-penetrating inhibitor of anaplastic lymphoma kinase
87In collaboration with ChugaiECC=European Cancer Congress
Patient population
ALK-positive crizotinib-naïve advanced NSCLC
ALK-positive advanced NSCLC patients who failed crizotinib
treatment
Tretment-naïve ALK-positive advanced NSCLC
Phase/study Phase I/II Phase I/II Phase IIIALEX
# of patients N=70 N=269 N=286
Design Part 1: Dose escalation monotherapy
Part 2: Monotherapy, dose selected based on the results of Part 1
Part 1: Dose escalation monotherapy
Part 2: Monotherapy, dose selected based on the results of Part 1
ARM A: alectinib 600mg BID ARM A: crizotinib 250mg BID
Primary endpoint
Safety and efficacy Safety and efficacy Progression-free survival
Status Study in crizotinib-naïve patients in Japan completed; crizotinib-failure patients in US ongoing
Data presented at ECC 2013 Japan study results: Lancet
Oncology 2013 Jun;14(7):590-8 Approved in Japan with a brand
name Alecensa July 2014
Phase II FPI Q2 2013 Expect FPI Q3 2014
Breakthrough therapy designation granted by the FDA June 2013
Anti-PDL1 (MPDL3280A, RG7446)Novel approach in cancer immunotherapy
88
Patient population
Metastatic NSCLC 2nd line
Locally advanced or metastatic NSCLC
PD-L1 positive
Locally advanced or metastatic NSCLC
PD-L1 positive
Locally advanced or metastatic NSCLC
(2nd/3rd line)
Non-small cell lung cancer
Phase/study Phase IIIOAK
Phase IIFIR
Phase IIBIRCH
Phase IIPOPLAR Phase I
# of patients N=850 N=130 N=300 N=300 N=32
Design RG7446 1200mg q3w docetaxel
Single arm study 1200mg of RG7446
q3w for maximum of 16 cycles
Single arm study 1200mg of RG7446
q3w for maximum of 16 cycles
ARM A: RG7446 1200mg IV q3w, up to 16 cycles
ARM A: DocetaxelIV q3w
RG7446 plus Tarceva1
Primary endpoint
Overall survival Overall response rate Objective response rate
Overall survival Safety
Status FPI Q1 2014 Recruitment completed Q2 2014
FPI Q1 2014 Recruitment completed Q2 2014
FPI Q1 2014
1Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC;
Anti-PDL1 (MPDL3280A, RG7446)Novel approach in cancer immunotherapy
89
Patient population
Untreated advanced renal cell carcinoma
Locally advanced or metastatic urothelial
bladder cancerSolid tumors Locally advanced or
metastatic solid tumors
Phase/study Phase II Phase II Phase I Phase I
# of patients N=150 N=330 N=154 N=200
Design ARM A: RG7446 plus Avastin
ARM B: RG7446; following PD: RG7446 plus Avastin
ARM C: sunitinib; following PD: RG7446 plus Avastin
Cohort 1: Treatment-naive and cisplatin-ineligible patients
Cohort 2: Patients with disease progression following or during platinum-containing treatment
ARM A: RG7446 + Avastin ARM B: RG7446 + Avastin
+ FOLFOX ARM C: RG7446 + Avastin
+ carboplatin+paclitaxel ARM D: RG7446 + Avastin
+ carboplatin+ pemetrexed ARM E: RG7446 + Avastin
+ carboplatin+ nab-paclitaxel
ARM A: RG7446 plus ipilimumab
ARM B: RG7446 plus interferon alpha-2b
Primary endpoint
Progression free survival Objective response rate Safety/PK Safety
Status FPI Q1 2014 FPI Q2 2014 FPI Q2 2012 FPI expected Q3 2014
Anti-PDL1 (MPDL3280A, RG7446)Novel approach in cancer immunotherapy
90
Patient population
Previously untreated metastatic melanoma
BRAF mutation positive
Locally advanced or metastatic tumors Solid tumors
Phase/study Phase I Phase I Phase I
# of patients N=44 N=90 N=344
Design Three-arm study with different doses of RG7446-Zelboraf1 combination
ARM A: Dose-finding –RG7446 plus cobimetinib2
ARM B: Dose-expansion -RG7446 plus cobimetinib
Dose escalation study
Primary endpoint
Safety/PK Safety Safety/PK
Status FPI Q4 2012 FPI Q4 2013 FPI Q2 2011 Initial efficacy data
presented at ASCO 2013 Updated data presented at
ECC 2013 Data from bladder cohort
presented at ASCO 2014
1Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2Cobimetinib in collaboration with Exelixis
Bcl-2 inhibitor (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor
91
Patient population
Relapsed or Refractory CLL Relapsed CLL and SLL
Relapsed/Refractory or previously untreated
CLL
Relapsed/Refractory or previously untreated
CLL
Phase/study Phase IIIMURANO Phase Ib Phase I Phase I
# of patients N=370 N=50 N=70 N=74
Design ARM A: RG7601 plus Rituxan
ARM B: Rituxan plus bendamustine
Dose-escalation study in combination with MabThera/Rituxan
RG7601 in combination with MabThera/Rituxan and bendamustine
RG7601 in combination with Gazyva
Primary endpoint
Safety/MTD Safety/MTD Safety/MTD Safety/MTD
Status FPI Q1 2014 FPI Q3 2012 Data presented at ASCO
2014
FPI Q2 2013 FPI Q1 2014
Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic LymphomaASH=American Society of Hematology; ASCO=American Society of Clinical Oncology
Bcl-2 inhibitor (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor
92
Patient population
Relapsed/Refractory CLL with 17p deletion
Relapsed or Refractory follicular non-Hodgkin’s lymphoma
Phase/study Phase II Phase II
# of patients N=100 N=156
Design Single-agent RG7601 ARM A: RG7601 plus Rituxan ARM B: RG7601 plus Rituxan plus
bendamustine ARM C: Rituxan plus bendamustine
Primary endpoint
Safety/MTD Overall response rate
Status FPI Q3 2013 Expect FPI Q3 2014
Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)
Bcl-2 inhibitor (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor
93
Patient population Front-line DLBCL Relapsed or Refractory NHL Relapsed/Refractory CLL and
NHL
Phase/study Phase I/II Phase I Phase I
# of patients N=230 N=40 N=121
Design ARM A: RG7601+R-CHOP ARM B: RG7601+G-CHOP
Dose escalation of RG7601 in combination with Rituxan and bendamustine
Dose-escalation study
Primary endpoint
Safety and efficacy Safety/MTD Safety/PK/Response rate
Status FPI Q2 2014 FPI Q2 2012 Study resumed Q3 2013
FPI Q2 2011 CLL and NHL data presented
at ASCO 2013 Updated CLL and SLL data
presented at ASH 2013 Updated CLL, SLL and NHL
(DLBCL and FL) data presented at ASCO 2014
Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic LymphomaASH=American Society of Hematology; ASCO=American Society of Clinical Oncology
Bcl-2 inhibitor (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor
94
Patient population
Relapsed/Refractory multiple myeloma
Relapsed/Refractory multiple myeloma
Acute myelogenous leukemia (AML)
Phase/study Phase I Phase I Phase I/II
# of patients N=30 N=30 N=54
Design Patients receiving Bortezomiband Dexamethasone as standard therapy:
Dose escalation cohort: RG7601+bortezomib+dexamethasone
Safety expansion cohort: RG7601+bortezomib+dexamethasone
Dose escalation cohort Safety expansion cohort
Dose escalation of RG7601
Primary endpoint
Safety/MTD Safety/MTD Overall response rate
Status FPI Q4 2012 FPI Q4 2012 FPI Q4 2013
Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)
Cobimetinib (RG7421, GDC-0973)Selective small molecule inhibitor of mitogen-activated protein kinase kinase
95
Patient population
Previously untreated metastatic melanoma
BRAF mutation positive
Metastatic melanomaBRAF mutation positive
Locally advanced or metastatic tumors
Locally advanced or metastatic tumors with
mutant KRAS
Phase/study Phase IIIcoBRIM
Phase IbBRIM7 Phase I Phase I
# of patients N=500 N=~100 N=90 N=50
Design ARM A: Zelboraf1 plus cobimetinib
ARM B: Zelboraf1 plus placebo
Dose escalation study evaluating Zelboraf1 plus cobimetinib
ARM A: Dose-finding -cobimetinib plus RG7446 (anti-PDL1)
ARM B: Dose-expansion - cobimetinib plus RG7446 (anti-PDL1)
Dose finding of cobimetinib plus RG7597 (anti-HER3/EGFR DAF)
Primary endpoint
Progression-free survival Safety/PK Safety Safety
Status Enrollment completed Q1 2014
Primary endpoint met July 2014
Data to be presented H2 2014
Enrollment completed Final data presented at
EADO and ASCO 2014
FPI Q4 2013 FPI Q4 2013
In collaboration with Exelixis1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2ipatasertib in collaboration with Array BioPharmaEADO=European Association of Dermato-Oncology; ASCO=American Society of Clinical Oncology
Pictilisib (RG7321, GDC-0941)Pan-PI3 kinase inhibitor with potential activity in multiple cancers
96
Patient population
2L ER-positive metastatic breast cancer
Previously untreated advanced or recurrent NSCLC
Locally recurrent or metastatic HER2-negative HR-positive
breast cancer
Phase Phase IIFERGI
Phase IIFIGARO
Phase IIPEGGY
# of patients N=340 N=302 N=180
Design ARM A: pictilisib plus hormonal therapy
ARM B: apitolisib plus hormonal therapy (ARM B discontinued)
ARM C: Hormonal therapy + placebo
ARM A: Pictilisib + carboplatin + paclitaxel
ARM B: Placebo + carboplatin + paclitaxel
ARM C: Pictilisib+ carboplatin + paclitaxel + bevacizumab
ARM D: Pictilisib+ carboplatin + paclitaxel + bevacizumab
ARM A: Pictilisib+ paclitaxel ARM B: Placebo + paclitaxel
Primary endpoint
Progression-free survival Progression-free survival Progression-free survival
Status Recruitment completed Q1 2014 FPI Q1 2012 Recruitment completed Q2 2014
Polatuzumab vedotin (RG7596)Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies
97
Patient population Non-Hodgkin's lymphoma Non-Hodgkin’s lymphoma
Phase Phase IIROMULUS Phase Ib
# of patients N=120 N=90
Design ARM A: RG7593 plus Rituxan ARM B: RG7596 plus Rituxan
Dose escalation study in combination with Rituxan and chemotherapy
Primary endpoint
Safety and anti-tumor activity Safety
Status Recruitment completed Q1 2014
Initial data presented at ASCO 2014
FPI Q4 2013
In collaboration with Seattle GeneticsASCO=American Society of Clinical Oncology
Taselisib(RG7604, GDC-0032)Beta isoform sparing PI3 kinase inhibitor targeting commonly mutated oncogene
98
Patient population
Solid tumors and HER2-negative HR-positive breast cancer
HER2-negative locally recurrent or metastatic breast cancer
PI3KCAmut-pos. 2L squamous NSCLC
Lung Master Protocol
Phase Phase I/II Phase I Phase IILung-MAP
# of patients N=260 N=65 N=120
Design Phase I RG7604 RG7604 plus letrozole or
fulvestrant
Phase II RG7604 (multiple doses) plus
letrozole or fulvestrant
RG7604 plus docetaxel RG7604 plus paclitaxel
RG7604 vs. chemo
Primary endpoint
Safety/PK/efficacy Safety Progression-free survival
Status Recruitment completed Q2 2014 Data presented at SABCS 2013 Biomarker data presented at
AACR 2014
FPI Q2 2013 FPI Q2 2014
SABCS=San Antonio Breast Cancer Symposium; AACR=American Association for Cancer Research
Bitopertin (GlyT-1, RG1678)A small molecule first-in-class glycin reuptake inhibitor (GRI)
99PANSS=Positive and Negative Syndrome Scale
Patient population
Sub-optimally controlled symptoms of schizophrenia Obsessive-compulsive disorder
Phase/study Phase IIINIGHTLYTE
Phase IISKYLYTE
# of patients N=600 N=99
Design Add-on therapy to anti-psychotics 52-week treatment period ARM A: bitopertin daily (10 mg) ARM B: bitopertin daily (20 mg) ARM C: Placebo
16-week treatment period Background therapy of selective serotonin
reuptake inhibitors (SSRI)•ARM A: bitopertin daily (30 mg)•ARM B: bitopertin daily (10 mg)•ARM C: Placebo
Primary endpoint
PANSS positive symptom factor at week 12 Change in total score on Yale-Brown Obsessive Compulsive Scale
Status FPI Q4 2010 10 mg dose arm met primary endpoint Q2 2014 Further steps under evaluation
FPI Q4 2012
Gantenerumab (RG1450)Fully human monoclonal antibody against amyloid-beta
100
Patient population Prodromal Alzheimer’s Disease Mild Alzheimer’s Disease
Phase/study Phase II/IIISCarlet RoAD
Phase IIIMarguerite Road
# of patients N=799 N=1,000
Design 104-week subcutaneous treatment period ARM A: Gantenerumab (225 mg) ARM B: Gantenerumab (105 mg) ARM C: Placebo
104-week subcutaneous treatment period ARM A: Gantenerumab ARM B: Placebo
Primary endpoint
Change in CDR-SOB at 2 years Sub-study: change in brain amyloid by PET at 2
years
Change in ADAS-Cog and ADCS-ADL at 2 years (co-primary)
Status Phase I PET data: Archives of Neurology 2012 Feb;69(2):198-207
Enrollment completed Q4 2013 Data expected in 2016
FPI Q1 2014
In collaboration with MorphosysCDR-SOB=Clinical Dementia Rating scale Sum of Boxes
Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin
101
Patient population Ulcerative colitis patients who are TNF naïve
Phase/studyPhase III
HIBISCUS IInduction study
Phase IIIHIBISCUS II
Induction study
Phase IIIGARDENIA
Sustained remission study
# of patients N=350 N=350 N=720
Design ARM A: etrolizumab 105mg SC q4w + adalimumab placebo
ARM B: etrolizumab placebo + adalimumab
ARM C: etrolizumab placebo + adalimumab placebo
ARM A: etrolizumab 105mg SC q4w + adalimumab placebo
ARM B: etrolizumab placebo + adalimumab
ARM C: etrolizumab placebo + adalimumab placebo
Time on treatment 54 weeks ARM A: etrolizumab 105mg SC q4w
+ placebo IV ARM B: placebo SC q4w +
adalimumab SC
Primary endpoint
Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10
Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10
Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS) at weeks 10, 30 and 54
Status Expect FPI Q3 2014 Expect FPI Q3 2014 Expect FPI Q3 2014
Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin
102
Patient population
UC patient who are TNF naïve and refractory or intolerant to immunosuppressant and/or corticosteroid
treatment
UC patient who are refractory or intolerant of TNF inhibitors
Phase/studyPhase IIILAUREL
Maintenance study
Phase IIIHICKORY
Induction and maintenance study
# of patients N=350 N=800
Design Induction phase: ARM A: open label etrolizumab 105mg SC q4w
Maintenance study: ARM B: etrolizumab 105mg SC q4w ARM C: placebo
Cohort 1 (open-label): ARM A: etrolizumab induction + placebo maintenance ARM B: etrolizumab induction + maintenance
Cohort 2 (blinded): ARM A: etrolizumab induction + maintenance ARM B: placebo induction + maintenance
Primary endpoint
Maintenance of remission (at week 62) among randomized patients in remission at Week 10 as determined by the Mayo Clinic Score (MCS)
Clinical Remission (Mayo Clinic Score, MCS) at Week 14 Remission maintenance (by MCS, at Week 66) among
patients with remission at Week 14
Status Expect FPI Q3 2014 FPI Q2 2014
UC=ulcerative colitis
Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin
103
Patient population Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis
Phase/studyPhase IISPRUCE
Open label extension study
Phase IIICOTTONWOOD
Open label extension study
# of patients N=116 N=2,600
Design Patients who were enrolled in EUCALYPTUS study and meet enrollment criteria will receive etrolizumab 105 sc q4w
Patients who were previously enrolled in etrolizumab phase III studies and meet enrollment criteria will receive etrolizumab 105 sc q4w
Primary endpoint Safety Long-term efficacy as determined by partial Mayo Clinic Score (pMCS)
Incidence of adverse events
Status Recruitment completed Expect FPI Q3 2014
HCV: Mericitabine, danoprevir, setrobuvirIFN-free combination of different direct-acting antivirals in treatment-naïve patients
104
Patient population
Hepatitis C patientsTreatment-naïve or null-responders to interferon-based treatment
Phase/study Phase IIANNAPURNA
# of patients N=110
Design ARM A: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine ARM B: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine ARM C: GT1a including setrobuvir, danoprevir, ritonavir and ribavirin ARM D: GT1b including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine ARM E: GT1b including setrobuvir, danoprevir, ritonavir and ribavirin
Primary endpoint Sustained virological response at week 12 after the end of the study treatment
Status FPI Q2 2012 Recruitment Part 1 completed in Q4 2012 Data presented at APASL 2014 Publication is expected in 2015
Mericitabine (RG7128) licensed from Pharmasset, now part of Gilead; Danoprevir=RG7227; Setrobuvir=RG7790APASL=Asian Pacific Association for the Study of the Liver
HCV: Danoprevir (RG7227)IFN-based triple regimen for treatment-naïve patients ofAsian origin conducted in China
105
Patient population
Treatment-naïve patients of Asian origin with chronic hepatitis C genotype 1 with or without cirrhosis
Phase/study Phase IIDAPSANG
# of patients N=61
Design Without cirrhosis: ARM A: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 12 weeks
With compensated cirrhosis: ARM B: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks
Primary endpoint Safety:
Status Recruitment completed Q4 2013 Study ongoing
In collaboration with Ascletis
106
Patient population
Geographic atrophy (GA) secondary to age-related macular degeneration
Phase/study Phase Ib/IIMAHALO
# of patients N=143
Design Part 1: Open-label Multiple dosing Part 2: Randomized ARM A: Lampalizumab injection ARM B: Sham injection
Primary endpoint
Part 1: Safety Part 2: Growth rate of GA lesions at month 18
Status Primary endpoint met Q3 2013 Efficacy data including biomarker presented at AAO 2013
AAO=American Academy of Ophthalmology
Lampalizumab (RG7417)Antibody fragment to selectively block activation of alternative complement pathway
Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13
107
Severe uncontrolled adult asthma
Patient population
Adult patients whoseasthma is uncontrolled with inhaled corticosteroids and a second controller medication
Phase/study Phase IIILAVOLTA I
Phase IIILAVOLTA II
# of patients N=1,050 N=1,050
Design Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up
ARM A: Lebrikizumab high dose ARM B: Lebrikizumab low dose ARM C: Placebo Patients will be tested for periostin level
Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up
ARM A: Lebrikizumab high dose ARM B: Lebrikizumab low dose ARM C: Placebo Patients will be tested for periostin level
Primary endpoint
Rate of asthma exacerbations during the 52-week placebo-controlled period
Rate of asthma exacerbations during the 52-week placebo-controlled period
Status FPI Q3 2013 FPI Q3 2013
Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13
108
Patient population
Adolescent patients whoseasthma is uncontrolled with inhaled
corticosteroids and a second controller medication
Idiopathic pulmonary fibrosis
Phase/study Phase IIIACOUSTICS
Phase IIRIFF
# of patients N=375 N=250
Design Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks with 52 week double-blind active treatment extension
ARM A: Lebrikizumab high dose, week 1-104 or week 52-104
ARM B: Lebrikizumab low dose, week 1-104 or week 52-104
ARM C: Placebo, week 1-52
ARM A: Lebrikizumab SC q4w ARM B: Placebo
Primary endpoint
Rate of asthma exacerbations during the 52-week placebo-controlled period
Progression-free survival
Status FPI Q3 2013 FPI Q4 2013
SOC=Standard of Care; OCS=Oral Corticosteroids
Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13
109
Patient population Adult asthma Adult asthma
mild-to-moderate patients
Phase/study Phase IIVOCALS
Phase IIISTRETTO
# of patients N=130 N=300
Design ARM A: Lebrikizumab SC q4w ARM B: Placebo
ARM A: Lebrikizumab SC q4w ARM B: Placebo ARM C: Montelukast
Primary endpoint
Relative change in OCS dose at week 44
Absolute change in FEV1 at week 12
Status FPI Q1 2014 FPI Q2 2014
Ocrelizumab (RG1594)2nd generation anti-CD20 monoclonal antibody
110
Patient population Relapsing multiple sclerosis (RMS) Primary progressive
multiple sclerosis (PPMS)
Phase/study Phase IIIOPERA I
Phase IIIOPERA II
Phase IIIORATORIO
# of patients N=800 N=800 N=630
Design 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg
iv followed by 600 mg iv every 24 weeks
ARM B: Interferon β-1a
96-week treatment period: ARM A: Ocrelizumab 2x 300 mg
iv followed by 600 mg iv every 24 weeks
ARM B: Interferon β-1a
120-week treatment period: ARM A: Ocrelizumab 2x 300 mg
iv every 24 weeks ARM B: Placebo
Primary endpoint
Annualized relapse rate at 96 weeks versus Rebif
Annualized relapse rate at 96 weeks versus Rebif
Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS)
Status Enrolment completed Q1 2013 Expect data in 2015
Enrolment completed Q1 2013 Expect data in 2015
Enrolment completed Q1 2013 Expect data in 2015
111111
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
Molecule MDM2 (4) antagonist(RG7388)
MDM2 (4) ant.IV prodrug(RG7775)
LSD1 inhibitor(RG6016)
Raf/MEK inhibitor(RG7304, CKI27)
Patient population Solid tumors Acute myeloid
leukemiaAdvanced cancers
including AML Acute Leukemia Solid tumors
Phase Phase I Phase I Phase I Phase I Phase I
# of patients N=100 N=100 N=90 N=30 N=52
Design Multiple ascending dose-escalation study
Multiple ascending dose-escalation study
Dose-escalation study ARM A: patients
with advanced solid tumors
ARM B: patients with r/r AML
Multiple ascending dose-escalation study
Dose-escalation to MTD
Primary endpoint
MTD MTD MTD MTD MTD and tumor assessment
Status Completed Q2 2013 Data presented at
ASCO 2014
FPI Q1 2013 FPI Q2 2014 FPI Q1 2014 Initiated Q4 2008 Enrolment stopped
in Q4 2010
Collaborator Oryzon Genomics, S.A. Chugai
Oncology development programmesSmall molecules
112ASCO=American Society of Clinical Oncology
Oncology development programmesMonoclonal antibodies
113
Molecule Anti-glypican-3 MAb(RG7686, GC33)
Patient population
Metastatic liver cancer(hepatocellular carcinoma)
2L metastatic liver cancer(hepatocellular carcinoma)
Phase Phase Ib Phase II
# of patients N= 40-50 N=171
Design Study US monotherapy Study Japan monotherapy Dose escalation study in combo with SOC
Adaptive design studyDouble blind randomized 2:1 RG7686 : placebo
Patients are stratified according to the level of GPC-3 expression in tumor
Primary endpoint
Safety and tolerability Progression-free survival
Status Recruitment completed Q4 2013 Dose escalation completed for US and Japan monotherapy
and combination therapy studies Patients continuing on combination treatment with SoC on
study
Recruitment completed Q1 2013 Results under internal review
Collaborator Chugai
SOC=standard of care
Oncology development programmesMonoclonal antibodies (continued)
114
Molecule GE-huMAb HER3(RG7116)
Patient population Solid tumors HER2-low and HER3-positive
metastatic breast cancer
Phase Phase I Phase I
# of patients N=105 N=40
Design Multiple ascending dose study with extension cohorts and imaging sub-study
Combination arms with HER1-targeted therapies (erlotinib, cetuximab)
Multiple ascending dose of RG7116 in combination with Perjeta and paclitaxel
Primary endpoint
Safety, PK Safety
Status FPI Q4 2011 Biomarker data presented at AACR 2013 Data presented at ASCO 2014
FPI Q3 2013
Oncology development programmesMonoclonal antibodies (continued)
115
Molecule Ang2-VEGF MAb(RG7221)
CSF-1R huMAb(RG7155)
CEA-IL2v(RG7813)
Patient population Solid tumors Metastatic colorectal
cancer Solid tumors and PVNS Solid tumors
Phase Phase I Phase IIMcCAVE Phase I/II Phase I
# of patients N≈80 N=140 N≈140 N~110
Design Multiple ascending dose study with extension cohorts in solid tumors to assess the PD effects and platinum resistant ovarian cancer
ARM A: Induction: Avastin+mFOLFOX-6; followed by maintenance: Avastin+5-FU/LV
ARM B: Induction: RG7221+mFOLFOX-6; followed by maintenance: RG7221+5-FU/LV
Multiple ascending dose study +/- paclitaxel with extension cohorts
Single and multiple dose escalation study with extension cohorts
Primary endpoint
Safety, PK PFS Safety, PK, PD & preliminary clinical activity
Safety, PK, PD
Status FPI Q4 2012 Dose escalation data
presented at ASCO 2014
FPI Q2 2014 FPI Q4 2011 Biomarker data presented
at AACR 2013 and AACR 2014
Data presented at ASCO 2014
FPI Q4 2013
ASCO=American Society of Clinical Oncology
Neuroscience development programmes
116
Metabolic glutamate receptor pathway
Molecule Decoglurant(mGlu2 NAM, RG1578)
Basimglurant(mGlu5 NAM, RG7090)
Patient population
Adjunctive Treatment of Major Depressive Disorder
Adjunctive Treatment of Major Depressive Disorder Fragile X Syndrome
Phase/study Phase IIArtDeCo
Phase IIMarigold
Phase IIFragxis
Phase IIFoXtail
# of patients N=480 N=300 N=180 N=45 Pediatric patients
Design ARM A: decoglurant 5 mg ARM B: decoglurant 15 mg ARM C: decoglurant 30 mg ARM D: matching placebo
ARM A: basimglurant 0.5 mg ARM B: basimglurant 1.5 mg ARM C: matching placebo
ARM A: basimglurant 0.5 mg ARM B: basimglurant 1.5 mg ARM C : matching placebo
ARM A: basimglurant dose A ARM B: basimglurant dose B ARM C : matching placebo
Primary Endpoint
Efficacy - Montgomery AsbergDepression Rating Scale
Efficacy - Montgomery AsbergDepression Rating Scale
Efficacy, safety and tolerability Safety Exploratory efficacy and
tolerability
Status Recruitment completed Data in-house under review
Study completed Data in-house under review Data presentation planned H2
2014
Recruitment completed Data in-house under review
Recruitment completed Data in-house under review
Neuroscience development programmes
117
Molecule PDE10A inhibitor(RG7203)
TAAR1 agonist(RG7410)
GABRA5 NAM(RG1662)
mGlu5 PAM(RG7342)
Patient population Schizophrenia Schizophrenia Down Syndrome Schizophrenia
Phase Phase I Phase I Phase IIBCLEMATIS Phase I
# of patients N=48 N= up to 56 (Part 1 and 2) N=180 N=93
Design Multiple dose, double-blind study in schizophrenia patients
ARM A: RG7203 plus risperidone ARM B: placebo plus risperidone
Part 1: Double-blind, randomized, placebo controlled, sequential multiple ascending dose study in HVs Part 2: Double-blind, randomized, placebo controlled, parallel group, multiple dose study in type 2 diabetes
For 26 weeks patients will receive:
ARM A: RG1662 120mg twice daily
ARM B: RG1662 120mg twice daily
ARM C: Placebo
Single ascending dose of RG7342
Primary endpoint
Safety, tolerability, PK Part 1: Safety and tolerability in HVs Part 2: Safety and tolerability in patients with type 2 diabetes mellitus
Cognition and adaptive behavior
Safety, tolerability, PK and food effect
Status FSI Q1 2014 Part 1 FSI July 2014 FPI Q2 2014 FPI July 2014
NAM=Negative allosteric modulator; HV= healthy volunteer
Neuroscience development programmes
118
MoleculeMonoamine oxidase type B
(MAO-B) inhibitor(RG1577, EVT-302)
V1 receptor antagonist(RG7314)
SMN2 splicing modifier(RG7800)
Patient population Alzheimer’s Disease Autism Spinal muscular atrophy
Phase Phase IIbMAyflOwer RoAD
Phase IIVANILLA Phase I
# of patients N=495 N=150 N=48
Design 52-week oral treatment ARM A: RG1577 (dose 1) ARM B: RG1577 (dose 2) ARM C: placebo
Multi-center, randomized, double-blind, placebo-controlled proof-of-concept study in individuals with Autism Spectrum Disorder (ASD)
Healthy volunteer study ARM A: RG7800 Single dose ARM B: Placebo
Primary endpoint
Changes in ADAS-Cog at 52 weeks
Safety and efficacy Safety, PK
Status Recruitment completed Q1 2014 FSI Q3 2013 FSI Q1 2014
Collaborator EvotecPTC Therapeutics/ SMA Foundation
Neuroscience development programmes
119
Molecule Anti-aSyn(RG7935, PRX002)
Patient population Parkinson’s disease
Phase Phase I Phase I
# of patients N=40 N=up to 60
Design Double-blind, placebo-controlled, single ascending dose study of RG7935/PRX002 in healthy subjects
Double-blind, placebo-controlled, multiple ascending dose study of RG7935/PRX002 in patients with Parkinson’s disease
Primary endpoint
Safety, tolerability, PK Safety and tolerability
Status FSI Q2 2014 FPI July 2014
Collaborator Prothena
Infectious diseases programmes
120
Molecule TLR7 agonist(RG7795)
LptD antibiotic(RG7929)
Patient population Chronic hepatitis B Pseudomonas infections
(including MDR strains)
Phase Phase I Phase II
# of patients N=50 N=~50
Design Healthy volunteer study ARM A: Single ascending dose
of RG7795 ARM B: Placebo
Patient study with RG7929
Primary endpoint
Safety Safety, PK/PD and efficacy
Status FPI Q4 2013 FPI Q4 2013 QIDP and fast track designation
granted Q2 2014
Collaborator Polyphor
QIDP=Qualified Infectious Disease Product designation
Metabolic development programmes
121
Molecule Inclacumab(P-selectin huMAb, RG1512)
Patient population
Prevention of saphenous vein graft diseasePatients undergoing coronary artery bypass graft
(CABG) surgery
Acute Coronary Syndrome (ACS) Patients undergoing percutaneous coronary
intervention (PCI)
Phase/study Phase IISELECT-CABG
Phase IISELECT-ACS
# of patients N=384 N=516
Design 32-week treatment period ARM A: Inclacumab (20 mg/kg) ARM B: Placebo
Single infusion ARM A: Inclacumab (5 mg/kg) ARM B: Inclacumab (20 mg/kg) ARM C: Placebo
Primary Endpoint
Sapheneous vein graft re-occlusion Procedural damage (troponin)
Status Recruitment completed Q2 2012 Data to be published in 2014
Recruitment completed Data presented at ACC 2013
Candidate for partnering-out
Collaborator Genmab
ACC=American College of Cardiology
Metabolic, ophthalmology and hemophilia development programmes
122
Molecule GLP-1/GIP dual agonist (MAR709, RG7697)
Aldosterone synthase inhibitor(RG7641)
Anti-VEGF/Ang2(RG7716)
Factor IX/X bispecific(RG6013, ACE910)
Patient population Type 2 diabetes Metabolic diseases Wet age-related macular
degenerationHemophilia
Study in Japanese patients
Phase/study Phase I Phase I Phase I Phase I
# of patients N=60 N=96 N=30 N=18
Design ARM A: RG7697 SC AMR B: placebo
ARM A: RG7641 single dose
ARM B: Placebo
Healthy volunteer study Single ascending dose of
RG7716
Multiple ascending dose study with extension cohort
Primary Endpoint
Safety, PK Safety Safety Safety, PK, PD
Status MAD study ongoing Recruitment completed Q2 2014
FPI Q4 2013 Recruitment completed Q2 2014 in Japan
Collaborator Marcadia Biotech, Inc. acquisition
123123
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
Oncology development programmesMonoclonal antibodies
124
Growth factor signaling
Molecule Anti-HER3 EGFR DAF MAb(RG7597)
Patient population
Metastatic/recurrent SCCHN
KRAS wild-type metastatic colorectal cancer
1L recurrent/metastatic squamous cell carcinoma
of head and neck
Locally advanced or metastatic tumors with
mutant KRAS
Phase/study
Phase IIMEHGAN
Phase IIDARECK Phase Ib Phase I
# of patients N=170 N=130 N=21 N=50
Design ARM A: RG7597 ARM B: Cetuximab
ARM A: RG7597+FOLFIRI ARM B:
Cetuximab+FOLFIRI
Evaluating safety/tolerability with two chemo backbones
Arm A: Cisplatin/5-FU Arm B:
Carboplatin/Paclitaxel
Dose finding of RG7597 plus cobimetinib1
Primary endpoint
Progression-free survival Progression-free survival Safety, DLT, PK Safety
Status Recruitment completed Q2 2013
Data to be presented at ESMO 2014
Recruitment completed Q4 2013
Recruitment completed Q2 2014
FPI Q4 2013
1cobimetinib in collaboration with ExelixisSCCHN=Squamous Cell Carcinoma of the Head and NeckFOLFOX=Folinic acid, Fluorouracil, Oxaliplatin; FOLFIRI=Folinic acid, Fluorouracil, Irinotecan
Oncology development programmesAntibody drug conjugates
125ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research
Antibody drug conjugates (ADCs)
Molecule Anti-STEAP1 ADC(RG7450)
Anti-MUC16 ADC(RG7458)
NME ADC(RG7882)
Patient population Prostate cancer Ovarian and pancreatic
cancer
Pt. resistant ovarian cancer or unrespectable pancreatic
cancer
Phase Phase I Phase I Phase I
# of patients N=67 N=57 N=75
Design Dose escalation study Dose escalation study Dose escalation study
Primary endpoint
Safety Safety/PK Safety/PK
Status FPI Q1 2011 Data presented at ASCO
2013-2014 and AACR 2014
Recruitment completed Q2 2014
Safety and PK data presented at AACR 2013
FPI Q2 2014
Collaborator
Seattle Geneticsand Agensys Seattle Genetics
Oncology development programmesAntibody drug conjugates (continued)
126
Antibody drug conjugates (ADCs)
Molecule Anti-NaPi2b ADC(RG7599)
Patient population NSCLC and ovarian cancer Platinum-sensitive ovarian cancer Platinum-resistant ovarian cancer
Phase Phase I Phase Ib Phase IIHERAEA
# of patients N=96 N=42 N=92
Design Dose escalation study Dose escalation of RG7599in combination with carboplatin, with or without Avastin
ARM A: RG7599 ARM B: Pegylated liposomal
doxorubicin
Primary endpoint
Safety Safety, PK Progression-free survival
Status FPI Q2 2011 Data presented at ASCO 2014
FPI Q4 2013 FPI Q1 2014
CollaboratorSeattle Genetics
ASCO=American Society of Clinical Oncology
Oncology development programmesAntibody drug conjugates (continued)
127
Antibody drug conjugates (ADCs)
Molecule Anti-methoselin ADC(RG7600)
Anti-ETBR ADC(RG7636)
Pinatuzumab vedotin (RG7593) vs. polatuzumab
vedotin (RG7596)
NME ADC(RG7841)
Patient population
Pancreatic and ovarian cancer
Metastatic or unresectable melanoma Non-Hodgkin's Lymphoma Refractory solid tumors
Phase Phase I Phase I Phase IIROMULUS Phase I
# of patients N=66-96 N=44-64 N=120 N=115
Design Dose escalation study Dose escalation study Pinatuzumab vedotin plus Rituxan
Polatuzumab vedotin plus Rituxan
Dose escalation study
Primary endpoint
Safety Safety Safety and anti-tumor activity
Safety
Status FPI Q4 2011 Data presented at ASCO
2014
Recruitment completed Q1 2014
Data presented at AACR 2014
Recruitment completed Q1 2014
Interim data presented at ASCO and EHA 2014
FPI Q2 2014
Collaborator Seattle Genetics
AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology
Oncology development programmesSmall molecules
128
Molecule Ipatasertib(AKT inhibitor, GDC-0068, RG7440)
Patient population Solid tumors 2L Castration-resistant
prostate cancer Solid tumors1L metastatic gastric or
gastroesophageal junction adenocarcinoma
Phase Phase Ib Phase IIA.MARTIN Phase Ib Phase II
JAGUAR
# of patients N=120 N=262 N=62 N=120
Design Dose escalation with: ARM A: Docetaxel ARM B: Fluoropyrimidine
plus oxaliplatin ARM C: Paclitaxel ARM D: Enzalutamide
ARM A: Ipatasertib(400mg) + abiraterone
ARM B: Ipatasertib (200mg) + abiraterone
ARM C: Placebo + abiraterone
Dose escalations study of ipatasertib in combination with cobimetinib* (MEK inhibitor)
ARM A: Ipatasertib + mFOLFOX6
ARM B: Placebo + mFOLFOX6
Primary endpoint
Safety Progression-free survival Safety/PK Progression-free survival
Status FPI Q3 2011 Data presented at ASCO
and ESMO 2012
FPI Q3 2013 FPI Q2 2012 Data presented at AACR
2014
FPI Q3 2013
Collaborator Array BioPharma
*cobimetinib in collaboration with ExelixismFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology; AACR=American Association for Cancer Research
Oncology development programmesSmall molecules (continued)
129
Molecule ChK1 inhibitor(RG7741,GDC-0575)
ERK inhibitor(RG7842, GDC-0994)
NME(RG7845, GDC-0853)
PI3 Kinase inhibitor (RG7666, GDC-0084)
Patient population
Solid tumors or lymphoma Solid tumors
B-cell lymphoma and chronic lymphocytic
leukemia
Progressive or recurrent high-grade
glioma
Phase I Phase I Phase I Phase I Phase I
# of patients N=170 N=78 N=121 N=68
Design Dose escalation study Stage 1: Dose escalation Stage 2: Cohort expansion
Stage 1: Dose escalation Stage 2: Cohort expansion
Dose escalation study
Primary endpoint
Safety/PK Safety, MTD, PK Safety/PK, MTD Safety/PK
Status FPI Q2 2012 FPI Q2 2013 FPI Q4 2013 FPI Q2 2012
Collaborator Array BioPharma
Immunology development programmes
130
Molecule Quilizumab(Anti-M1 prime, RG7449)
anti-IL17(RG7624)
Patient population
Allergic asthma - inadequately controlled Chronic spontaneous urticaria Autoimmune diseases
Phase/study Phase IIbCOSTA
Phase IIQUAIL Phase Ib
# of patients N=560 N=30 N=21
Design SC administration on top of SOC ARM A: Quilizumab 300mg ARM B: Quilizumab 150mg ARM C: Quilizumab 450mg ARM D: Placebo
ARM A: Quilizumab sc ARM B: Placebo sc
• Randomized, double-blind, placebo-controlled, multiple ascending dose escalation study
Primary endpoint
Rate of protocol-defined exacerbations from baseline to week 36
Efficacy and safety • Safety and tolerability
Status Recruitment completed Q3 2013 Recruitment completed Q2 2014 • Enrolment completed Q2 2012• Next study in preparation
Collaborator NovImmune
SOC=Standard of Care
Neuroscience development programmes
131
Molecule Crenezumab(Anti-Αβ, RG7412)
Patient population Alzheimer’s Disease Alzheimer’s Prevention initiative
(API) Colombia
Phase/studyPhase IIABBY
Cognition study
Phase IIBLAZE
Biomarker study
Phase IICognition study
# of patients N=450 N=91 N=300
Design ARM A: Crenezumab sc ARM B: Crenezumab iv ARM C: Placebo
ARM A: Crenezumab sc ARM B: Crenezumab iv ARM C: Placebo
ARM A: 100 carriers receive crenezumab sc
ARM B: 100 carriers receive placebo ARM C: 100 non-carriers receive
placebo
Primary endpoint
Change in cognition (ADAS-cog) and Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score from baseline to week 73
Change in brain amyloid load from baseline to week 69
Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score
Status Enrolment completed Q3 2012 Data presented at AAIC 2014
Enrolment completed Q3 2012 Cognition data presented at AAIC 2014 Biomarker data to be presented at
CTAD 2014
FPI Q4 2013
Collaborator AC Immune AC Immune and Banner Alzheimer’s Institute
AAIC=Alzheimer’s Association International Conference; CTAD=Clinical Trials on Alzheimer’s Disease
Metabolism and infectious diseases development programmes
132
Molecule Anti-CMV(RG7667)
Anti-Flu A(RG7745)
Patient population
Prevention of cytomegalovirus disease in kidney transplant
recipientsInfluenza
Phase/study Phase II Phase IIa
# of patients N=120 N=100
Design ARM A: RG7667 ARM B: Placebo
Healthy volunteers in an influenza challenge model
ARM A: RG7745 ARM B: Placebo ARM C: Tamiflu
Primary endpoint
Safety, clinical activity Reduction in viral activity
Status FPI Q4 2012 Enrollment completed Q2 2014
Data positive with 98% reduction of viral load at 3600mg dose
Presented at ISIRV 2014
ISIRV=International Society for Influenza and other Respiratory Virus Diseases
133133
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
Geographical sales split by divisions and Group*
134
CHFm HY 2014 HY 2013 % change CER
Pharmaceuticals Division 17,834 18,162 +4
United States 7,572 7,553 +5Europe 4,775 4,652 +3Japan 1,581 1,672 +7International 3,906 4,285 +2
Diagnostics Division 5,140 5,133 +6
United States 1,147 1,139 +6Europe 2,082 2,064 +2Japan 222 242 +4International 1,689 1,688 +12
Group 22,974 23,295 +5
United States 8,719 8,692 +5Europe 6,857 6,716 +3Japan 1,803 1,914 +6International 5,595 5,973 +5
* Geographical sales split shown here does not represent operational organization; CER=Constant Exchange Rates134
135
Pharma Division sales HY 2014 (vs. 2013)Top 20 products
CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER MabThera/Rituxan 3,360 4 1,624 3 1,018 7 104 0 614 5Avastin 3,097 6 1,300 6 983 5 332 10 482 8Herceptin 3,082 6 937 10 1,138 3 130 4 877 6Lucentis 828 6 828 6 - - - - - -Tarceva 651 -1 325 5 154 -12 49 22 123 -8Pegasys 582 -15 137 -28 144 -26 32 31 269 -2Actemra/RoActemra 568 22 180 26 207 20 100 24 81 15Xeloda 474 -34 159 -47 58 -64 44 -9 213 -3Xolair 437 19 437 19 - - - - - -CellCept 413 -6 95 -6 110 -7 28 -5 180 -6Perjeta 388 276 237 183 92 423 37 - 22 *Tamiflu 372 3 188 -7 72 * 62 -21 50 -23Activase/TNKase 359 11 335 12 - - - - 24 8Valcyte/Cymevene 353 12 188 16 92 8 - - 73 6Pulmozyme 278 6 181 6 62 1 0 - 35 10NeoRec./Epogin 231 -8 - - 98 -12 29 -36 104 9Kadcyla 227 188 143 83 63 * 9 - 12 *Mircera 203 11 - - 52 4 94 9 57 20Zelboraf 155 -5 36 -43 100 10 - - 19 73Madopar 135 -9 0 - 53 -5 8 -1 74 -11
Global US Europe Japan International
CER=Constant Exchange Rates * over +500%
CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER
Erivedge 57 111 35 33 19 * - - 3 *
Gazyva 18 - 18 - - - - - - -
0 0 - - - - - - - - -
Global US Europe Japan International
Pharma Division sales HY 2014 (vs. 2013)Recently launched products
136CER=Constant Exchange Rates * over +500%
Q2/13 Q3/13 Q4/13 Q1/14 Q2/14
MabThera/Rituxan 0 12 7 3 5Avastin 13 14 13 9 4Herceptin 0 7 7 3 9Lucentis 18 21 22 8 4Tarceva 9 5 4 -5 3Pegasys -24 -16 -20 -19 -10Actemra/RoActemra 33 33 23 23 21Xeloda 3 6 -3 -19 -50Xolair 10 14 17 15 22CellCept 1 -2 -10 -1 -11Perjeta * 262 394 274 277Tamiflu 44 115 -27 9 -36Activase/TNKase 3 18 19 -1 26Valcyte/Cymevene 8 0 26 12 12Pulmozyme 7 0 18 3 8NeoRec./Epogin -20 -16 -14 -9 -8Kadcyla - - - 474 105Mircera 35 29 23 21 2Zelboraf 46 38 26 -2 -9Madopar -4 3 9 -20 3
Pharma Division CER sales growth1 in %Global top 20 products
1371 Q2-Q4/13 vs. Q2-Q4/12; Q1-Q2/14 vs. Q1-Q2/13 CER=Constant Exchange Rates * over 500%
US Europe Japan InternationalQ3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
MabThera/Rituxan 20 2 -2 8 6 0 6 8 8 8 20 -17 3 26 12 -2Avastin 10 4 6 6 17 9 8 2 15 12 27 -5 19 49 7 9Herceptin 14 3 4 17 -1 -2 2 4 7 11 23 -12 8 21 0 12Lucentis 21 22 8 4 - - - - - - - - - - - -Tarceva 5 -8 -6 16 0 -3 -12 -12 8 25 42 6 13 27 -6 -9Pegasys -51 -55 -40 -14 -14 -14 -19 -32 -22 -28 16 45 18 1 -7 3Actemra/RoActemra 33 20 22 30 26 21 20 20 26 24 49 5 59 31 3 28Xeloda 8 -8 -15 -80 1 -9 -57 -71 3 0 8 -23 10 9 -3 -2Xolair 14 17 15 22 - - - - - - - - - - - -CellCept 13 5 -7 -6 -11 -5 -10 -5 13 8 5 -14 -5 -24 6 -16Perjeta 129 201 161 205 * * * 287 - - - - - * * *Tamiflu * -24 -9 22 -76 - * -71 -73 -47 -17 -74 -17 -72 -8 -44Activase/TNKase 19 22 0 27 - - - - - - - - -1 -13 -4 19Valcyte/Cymevene 10 19 26 8 -22 28 5 10 - - - - 3 38 -7 24Pulmozyme 6 16 2 10 6 1 2 -1 29 12 150 - -25 41 10 9NeoRec./Epogin - - - - -26 -19 -14 -10 -22 -22 -26 -45 3 -2 7 12Kadcyla - - 315 16 - - - * - - - - - - - *Mircera - - - - 74 29 8 -1 26 21 36 -12 11 20 8 32Zelboraf 12 -1 -40 -46 36 17 12 8 - - - - 489 425 98 56Madopar - - - - 2 -1 -9 -2 5 3 4 -6 3 18 -29 7
Pharma Division CER sales growth1 in %Top 20 products by region
1381 Q3 2013 - Q4 2013 vs. 2012, Q1 2014 – Q2 2014 vs. 2013 CER=Constant Exchange Rates * over +500%
CER sales growth (%)Quarterly development
139CER=Constant Exchange Rates
2013 vs. 2012 2014 vs. 2013Q1 Q2 Q3 Q4 Q1 Q2
Pharmaceuticals Division 7 4 9 7 4 4
United States 13 7 16 5 3 8Europe 1 2 3 2 5 1Japan 2 2 4 2 19 -4International 8 2 5 18 1 3
Diagnostics Division 1 4 7 5 7 5
Roche Group 6 4 8 7 5 4
140
HY 2014: Oncology franchise
CER=Constant Exchange Rates
0.0
2.0
4.0
6.0
8.0
10.0
12.0
HY 12 HY 13 HY 14
CHFbn
US Europe International Japan
+6%
+5%
+5%
2014 vs. 2013 CER
+6%
+10%
HY 2014 sales of CHF 11.14bn
US
• HER2 Franchise (Perjeta: sustained growth of US patient shares), Avastin driving growth and performance
Europe
• Growth mainly driven by Perjeta and Kadcyla
International
• Strong growth for Avastin and Herceptin
Japan
• Growth driven largely by Avastin
141
MabThera/Rituxan
HY 2014 sales of CHF 3.360bn
• US and Europe: stable market shares in approved indications
CER=Constant Exchange Rates
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
HY 10 HY 11 HY 12 HY 13 HY 14
CHFbnGlobal sales
+4%CER growth
US +3%
Europe +7%
Japan 0%
International +5%
Regional sales CER growth
142
Xeloda
CER=Constant Exchange Rates
HY 2014 sales of CHF 0.474bn
• US: LoE impacts: loss of exclusivity Feb 2014
• Europe: LoE impacts: loss of exclusivity Dec 2013
0.0
0.2
0.4
0.6
0.8
1.0
HY 10 HY 11 HY 12 HY 13 HY 14
CHFbnGlobal sales
-34%CER growth
US -47%
Europe -64%
Japan -9%
International -3%
Regional sales CER growth
143
Tarceva
CER=Constant Exchange Rates
HY 2014 sales of CHF 0.651bn
• US: reversal of sales provisions• Europe: increased competition in 1L EGFR Mut+ market • International: local competition in China
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
HY 10 HY 11 HY 12 HY 13 HY 14
CHFbnGlobal sales
-1%CER growth
US +5%
Europe -12%
Japan +22%
International -8%
Regional sales CER growth
144
HY 2014: Immunology franchise
CER=Constant Exchange Rates
HY 2014 sales of CHF 2.389bn
0.0
0.5
1.0
1.5
2.0
2.5
HY 12 HY 13 HY 14
CHFbn
US Europe International Japan
+15%
+7%
+4%
2014 vs. 2013 CER
+11%
+9%
• Strong growth of Actemra/RoActemra and MabThera/Rituxan, CellCept declining
Actemra/RoActemra
• EU: growth driven by a strong mono patient shares, very encouraging SC
• US: growth is driven by strong IV demand and SC patient share uptake (80% of new patients)
CellCept• Decline of sales due to patent expiry key
EU countries end 2010
145
HY 2014: Infectious diseases
CER=Constant Exchange Rates
HY 2014 sales of CHF 1.555bn
Pegasys sales in Q2 are decreasing at lower rates than previous Qs.
• 2nd generation uptake in the US has driven this change.
• Lower and shorter uptake of 2nd generation IFN based are driving sales decrease in Germany and France.
• Solid growth in several LATAM countries driven by market growth with 1st generation DAAs.
0.0
0.4
0.8
1.2
1.6
2.0
HY 12 HY 13 HY 14
CHFbn
US Europe International Japan
-8%
-1%
-5%
2014 vs. 2013 CER
-5%
-2%
Tamiflu quarterly sales 2010 - 2014Retail and Governments/Corporations
146
CHFm
Retail
Governments & Corporations
422
17091
17 19 345 46
10 8 531 33
1 2 767
11
95
23
7
48
233
7
-6
12177
26 15
288 302
44 32
214
277
17
-100
100
200
300
400
500
600
Q110
Q210
Q310
Q410
Q111
Q211
Q311
Q411
Q112
Q212
Q3 12 Q412
Q113
Q213
Q313
Q413
Q114
Q214
147147
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
148CER=Constant Exchange Rates¹ Europe, Middle East and Africa
Diagnostics Division CER growth By Region and Business Area (vs. 2013)
Professional Diagnostics 2,904 9 600 9 1,305 4 999 15
Diabetes Care 1,140 0 210 -6 718 0 212 6
Molecular Diagnostics 762 4 268 8 305 -1 189 4
Tissue Diagnostics 334 9 194 5 95 14 45 18
Diagnostics Division 5,140 6 1,272 6 2,423 2 1,445 12
RoW
CHFm growth CHFm growth
Global North America EMEA¹
CHFm growth CHFm growth% CER % CER % CER % CER
149CER=Constant Exchange Rates¹ versus same period of prior year
Diagnostics Division quarterly sales and CER growth1
Professional 1,345 4 1,480 8 1,426 9 1,521 10 1,392 9 1,512 8 Diagnostics
Diabetes 539 -5 666 -4 576 3 678 -4 538 5 602 -4 Care
Molecular 378 -3 403 6 383 4 416 3 370 4 392 3 Diagnostics
Tissue 157 7 165 4 159 8 184 10 156 4 178 14 Diagnostics
Dia Division 2,419 1 2,714 4 2,544 7 2,799 5 2,456 7 2,684 5
Q4 13 Q1 14Q1 13 Q2 13 Q3 13CHFm % CER CHFm % CER CHFm % CER
Q2 14CHFm % CER CHFm % CER CHFm % CER
150CER=Constant Exchange Rates
HY 2014: Diagnostics Division salesGrowth driven by Professional Diagnostics
Molecular Diagnostics 15%
Professional Diagnostics 56%
Tissue Diagnostics 6%
Diabetes Care 23%
CHF 5,140m CER sales growth
6%
0%
9%
4%
9%
DiagnosticsDivision
DiabetesCare
ProfessionalDiagnostics
MolecularDiagnostics
TissueDiagnostics
762
3342,904
1,140
151CER=Constant Exchange Rates¹ Europe, Middle East and Africa
HY 2014: Diagnostics Division salesGrowth driven by Asia Pacific and North America
North America 25%
Japan 4%
EMEA1 47%
Asia Pacific 17%
Latin America 7%
CHF 5,140m CER sales growth
6%
6%
2%
11%
15%
4%
DiagnosticsDivision
NorthAmerica
EMEA¹
LatinAmerica
AsiaPacific
Japan
1,272
346
877
2222,423
152CER=Constant Exchange Rates
Professional DiagnosticsStrong growth driven by Immunodiagnostics
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
HY 12 HY 13 HY 14
CHFbn
Immunodiagnostics Clinical Chemistry POC products Other
+12%
+9%
+2%
2014 vs. 2013 CER growth
+9%
+4%
153CER=Constant Exchange Rates
Diabetes CareAdapting to a challenging market environment
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
HY 12 HY 13 HY 14
CHFbn
Blood Glucose Monitoring Other
-1%
+7%
2014 vs. 2013 CER growth
0%
2014 vs. 2013 CER growth
154CER=Constant Exchange Rates
Molecular DiagnosticsGrowth driven by Virology and Blood Screening
0.0
0.2
0.4
0.6
0.8
HY 12 HY 13 HY 14
CHFbn
Other HPV & MicrobiologyBlood Screening Biochem Reag & qPCR & NAP SystemsVirology
+4%
+5%
+7%
+2%
2014 vs. 2013 CER growth
+16%
-10%
155CER=Constant Exchange Rates¹ Europe, Middle East and Africa 2 Asia Pacific
Tissue DiagnosticsStrong growth in EMEA1 and APAC2
0.0
0.1
0.2
0.3
0.4
HY 12 HY 13 HY 14
CHFbn
Advanced Staining Primary Staining Other
2014 vs. 2013 CER growth
+9%
+8%
+1%
2014 vs. 2013 CER growth
+27%
2014: Key product launchesProfessional Diagnostics
156
Product Description Region
cobas m 511 Fully integrated and automated Hematology system EU
cobas 6500 (u 701) Automated urinalysis work area platform including u701 microscopy analyzer
EU
Syphilis Immunoassay for the detection of Treponema pallidum EU
PE Prognosis Claim extension for short-term prediction, rule in/out of Preeclampsia in pregnancy
EU
Anti Mullerian Hormone
Fully automated test for the assessment of ovarian reserve for fertility
EU
Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors
2014: Key product launchesDiabetes Care
157
Product Description Region
Accu-Chek Connect bG meter that connects wirelessly via Bluetooth to a smartphone app and cloud to transmit bG values
EU
Accu-Chek Insight Next generation insulin delivery system combining an insulin pump and a blood glucose meter that functions as a pump remote control
EU
Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors
158
2014: Key product launchesMolecular Diagnostics
Product Description Region
cobas 6800/8800 Next generation PCR platform for molecular testing in virology and blood screening, serving mid to high volumes
WW*
MPX 2.0 Next generation multiplex test for blood screening for HIV, HCV and HBV
US
HSV 1 and 2 test Detection of Herpes Simplex Virus on cobas 4800 platform EU
MRSA/SA test Detection of MRSA/SA on cobas 4800 EU
C-difficile test Detection of C-difficile on cobas 4800 US
* excluding US
Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors
159
2014: Key product launches Tissue Diagnostics
Product Description Region
Connect-V Middleware providing connectivity for RTD instruments to simplify interfacing and connectivity to laboratory and hospital information systems
WW
Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors
160160
Pipeline summary
Marketed products additional indications
Global Development late-stage trials
pRED (Roche Pharma Research & Early Development)
gRED (Genentech Research & Early Development)
Roche Group HY 2014 sales
Diagnostics
Foreign exchange rate information
0.870.890.910.930.950.970.99
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
0.870.890.910.930.950.970.99
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
-4%
Year-To-Date averages
Monthly averages
2013
2013
CHF / USD
2014
2014
-5%
161
0.87
0.89
0.91
0.93
0.95
0.97
0.99
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
monthly avg 2013
-5%
CHF / USD
monthly avg 2014
avg full year 2013
avg HY 2013
avg HY 2014
162
1.21
1.22
1.23
1.24
1.25
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
1.21
1.22
1.23
1.24
1.25
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Year-To-Date averages
Monthly averages
2013
2013
CHF / EUR
2014
2014
0% -1%
163
1.21
1.22
1.23
1.24
1.25
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
CHF / EUR
monthly avg 2014
monthly avg 2013
-1%avg full year 2013
avg HY 2014
avg HY 2013
164
HY 14 HY 13 HY 14 vs. HY 13
USD 0.89 0.94
EUR 1.22 1.23
JPY 0.87 0.98
Average exchange rates
-14% -12% -10% -8% -6% -4% -2% 0%
165
4.5%5.0%
-1.4%-0.8%
Q1 HY YTD 9 FY
Development ofaverage exchange rates versus prior year periodCHF / EUR -0.4% -0.7%CHF / USD -4.0% -4.8%CHF / JPY -13.9% -11.4%
Differencein CHF / CER -5.8%p -5.9%p
growth
CHFgrowth
CERgrowth
Salesgrowth2014
vs. 2013
Exchange rate impact on sales growthIn H1 2014 negative impact from USD, Latin American currencies and JPY
166CER=Constant Exchange Rates
4.0%5.0%
-1.9%-0.8%
Q1 Q2 Q3 Q4
Development ofaverage exchange rates versus prior year periodCHF / EUR -0.4% -0.9%CHF / USD -4.0% -5.6%CHF / JPY -13.9% -8.9%
Exchange rate impact on sales growthIn H1 2014 negative impact from USD, Latin American currencies and JPY
Differencein CHF / CER -5.8%p -5.9%p
growth
CHFgrowth
CERgrowth
Salesgrowth2014
vs. 2013
CER=Constant Exchange Rates167
CERsales
growthHY 2014
vs.HY 2013
Exchange rate impact on sales growthNegative impact from USD, Latin American currencies and JPY
+4.5% -2.0%
-1.2%-1.3%
-0.7%
-0.4%-1.4%
-1.0%
-0.8%
-0.4% -0.1%
CER USD Lat-Am JPY As-Pac OtherEurope
Other EUR CHF
CHFsales
growthHY 2014
vs.HY 2013
168CER=Constant Exchange Rates